HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use EFAVIRENZ. EMTRICITABINE. AND TENOFOVIR DISOPROXII FUMARATE TABLET safely and effectively. See full prescribing information for EFAVIRENZ, EMTRICITABINE. AND TENOFOVIR DISOPROXIL FUMARATE TABLET.

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2006

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for

complete boxed warning. Severe acute exacerbations of hepatitis B virus (HBV) have been reported in patients coinfected with HBV and HIV-1 who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet. If appropriate, initiation of antihepatitis B therapy may be warranted.

Warnings and Precautions

Nervous System Symptoms (5.6) 10/2019 Immune Reconstitution

10/2019 Syndrome (5.12)

Efavirenz, emtricitabine and tenofovir drug combination of efavirenz (EFV), a fat: Observed in patients receiving and Precautions (5.7)]. non-nucleoside reverse transcriptase antiretroviral therapy. (5.13) inhibitor, and emtricitabine (FTC) and ------ ADVERSE REACTIONS ------both HIV-1 nucleoside analog reverse (incidence greater than or equal to 10%) transcriptase inhibitors and is indicated as absorbed in an extension of childbearing potential *(see Warnings and Precautions (5.8), Use in Specific Populations (8.1, 8.3)).* transcriptase inhibitors, and is indicated as observed in an active-controlled clinical 2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg a complete regimen or in combination with trial of EFV, FTC, and TDF are diarrhea, Efaviren other antiretroviral agents for the treatment nausea, fatigue, headache, dizziness, patients weighing at least 40 kg. (1) and rash. (6.1)

- Testing: Consult Full Prescribing contact Exelan Pharmaceuticals, Inc. at recommendations prior to initiation or www.fda.gov/medwatch. and during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. (2.1)
- Recommended dosage in adults and pediatric patients weighing at least 40 kg: One tablet once daily taken orally • HIV-1 on an empty stomach, preferably at
- bedtime. (2.2) • Renal impairment: Not recommended in patients with estimated creatinine
- clearance below 50 mL/min. (2.3) Hepatic impairment: Not recommended
- in patients with moderate to severe hepatic impairment. (2.4) Dosage adjustment with rifampin

Efavirenz, Emtricitabine and

Tenofovir disoproxil fumarate Tablets

PI009 Rev 02.indd

coadministration: An additional 200 mg/ day of efavirenz is recommended for patients weighing 50 kg or more. (2.5)

-- DOSAGE FORMS AND STRENGTHS ---Tablets: 600 mg of efavirenz, 200 mg of

- Previously demonstrated hypersensitivity recommended. (8.2)
- Coadministration with elbasvir/
- grazoprevir. (4)
- ----- WARNINGS AND PRECAUTIONS -----• Rash: Discontinue if severe rash
- develops. (5.2, 6.1) Hepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying hepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of hepatic failure, a few occurred in patients with no pre-existing hepatic disease. (5.3, 6.2, 8.7)

 Risk of adverse reactions or loss of virologic response due to drug interactions: Consult full prescribing information prior to and during treatment for important potential drug interactions. Consider alternatives to Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablets in patients taking other medications with a known risk of Torsade de Pointes or in patients at higher risk of Torsade de Pointes. (5.4)

• Serious psychiatric symptoms: Immediate medical evaluation is

recommended. (5.5, 6.1) Nervous system symptoms (NSS); NSS are frequent, usually begin 1-2 days after initiating therapy, and resolve in 2-4 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset of psychiatric symptoms. (2.2,

5 6) New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Prior to 3 DOSAGE FORMS AND STRENGTHS initiation and during use of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, assess serum creatinine. estimated creatinine clearance urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Avoid administering Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with concurrent or recent use of

nephrotoxic drugs. (5.7) Embryo fetal toxicity: Fetal harm may occur when administered to a pregnant woman during the first trimester. Avoid pregnancy while receiving Efavirenz. emtricitabine and tenofovir disoproxil fumarate tablet and for 12 weeks after discontinuation. (5.8, 8.1)

 Decreases in bone mineral density fracture or other risk factors for fumarate tablet. osteoporosis or bone loss. (5.9)

with a history of seizures. (5.10)

 Lactic acidosis/severe hepatomegaly with steatosis: Discontinue treatment in patients who develop symptoms or laboratory findings suggestive of lactic weighing at least 40 kg. acidosis or pronounced hepatotoxicity. 2 DOSAGE AND ADMINISTRATION

> Immune reconstitution syndrome: treatment (5.12)

----- DOSAGE AND ADMINISTRATION ----- To report SUSPECTED ADVERSE REACTIONS, 2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment

----- DRUG INTERACTIONS -----prior to and during treatment for important potential drug interactions.

(4, 5, 4, 7)inhibitors: protease Coadministration of Efavirenz, Emtricitabine and Tenofovir disoproxil **3 DOSAGE FORMS AND STRENGTHS** increases tenofovir concentrations. Monitor for evidence of tenofovir 4 CONTRAINDICATIONS toxicity. Coadministration of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with either atazanavir or atazanavir and ritonavir is not

recommended. (7.3) ---- USE IN SPECIFIC POPULATIONS ----- 5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV

(e.g., Stevens-Johnson syndrome, • Females and Males of Reproductive decompensation and liver failure.

FULL PRESCRIBING INFORMATION: CONTENTS' WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B

- 1 INDICATIONS AND USAGE DOSAGE AND ADMINISTRATIO Testing Prior to Initiation and During
- reatment with Efavirenz, Emtricit enofovir disoproxil fumarate tablet 2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg
- 2.3 Not Recommended in Patients with loderate or Severe Renal Impairmer 2.4 Not Recommended in Patients with
- Moderate to Severe Hepatic Impairment 2.5 Dosage Adjustment with Rifampin
- 4 CONTRAINDICATIONS
- WARNINGS AND PRECAUTIONS 5.1 Severe Acute Exacerbation of Hepatitis B in atients Coinfected with HIV-1 and HBV
- 5.3 Hepatotoxicity 5.4 Risk of Adverse Reactions or Los
- of Virologic Response Due to Drug
- Psychiatric Symptom 6 Nervous System Symptoms 7 New Onset or Worsening Renal Impairment
- B Embryo-Fetal Toxicity Bone Loss and Mineralization Defects
- 5.11 Lactic Acidosis/Severe Hepatomegaly with Steatosis
- 5.12 Immune Reconstitution Syndrome 5.13 Fat Redistribution

FULL PRESCRIBING INFORMATION

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS E (BMD): Consider assessment of BMD Severe acute exacerbations of hepatitis B virus (HBV) have been reported in patients who are coinfected in patients with a history of pathological with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), which are components of Efavirenz, Emtricitabine and Tenofovir disoproxil

6 ADVERSE REACTIONS

DBUG INTERACTIONS

Interactions

8.2 Lactatior

10 OVERDOSAGE

11 DESCRIPTION

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Renal Impairmen

8.7 Hepatic Impairment

12 CLINICAL PHARMACOLOGY

12 2 Pharmacodynami

12.4 Microbiology

of Fertility

14 CLINICAL STUDIES

13 NONCLINICAL TOXICOLOGY

2.3 Pharmacokinetics

12.1 Mechanism of Action

6.2 Postmarketing Experience

7.4 Efavirenz Assay Interference

USE IN SPECIFIC POPULATION

.2 Drugs Affecting Renal Function

3 Established and Potentially Significant Drug

8.3 Females and Males of Reproductive Potential

13.1 Carcinogenesis, Mutagenesis, Impairmen

13.2 Animal Toxicology and/or Pharmacology

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

prescribing information are not listed

* Sections or subsections omitted from the full

Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in • Convulsions: Use caution in patients | patients who are coinfected with HIV-1 and HBV and discontinue Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is indicated as a complete regimen or in nation with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients

------ INDICATIONS AND USAGE ------- May necessitate further evaluation and hepatitis B virus infection [see Warnings and Precautions (5.1)]. Prior to initiation and during use of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, on a Patients receiving Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet should be alerted to the clinical significance are unknown.

protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings tumarate tablet is used concomitantly with alcohol or psychoactive drugs. Monitor hepatic function prior to and during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil drowsiness should avoid potentially hazardous tasks such as driving or operating machinery.

fumarate tablet [see Warnings and Precautions (5.3)]. tenofovir disoproxil fumarate (TDF), Most common adverse reactions Perform pregnancy testing before initiation of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is a three-drug fixed-dose combination product containing 600 mg of etavirenz (EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet wirne protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Efavirenz, the chronic disease and the chronic subjects the chronic subject subjects the chronic subject subject subjects the chronic subject subject subject subject subjects the chronic subj of HIV-1 infection in adults and pediatric depression, insomnia, abnormal dreams, in adults and pediatric patients weighing at least 40 kg is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may improve the tolerability of nervous system symptoms [see Clinical Pharmacology renal impairment (estimated creatinine clearance below 50 mL/min).

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is not recommended in patients with moderate Information for important testing **1-866-604-3268 or FDA at 1-800-FDA-1088** or severe renal impairment (estimated creatinine clearance below 50 mL/min) *(see Warnings and Precautions* .7), Use in Specific Populations (8.6)].

2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is not recommended in patients with moderate Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness ma • Consult Full Prescribing Information to severe hepatic impairment (Child-Pugh B or C) Isee Warnings and Precautions (5.3) and Use in Specific manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in patients Populations (8.7)].

2.5 Dosage Adjustment with Rifampin abine and Tenofovir disoproxil fumarate tablet is co-administered with rifampin in patients

significant decreases in renal function or evidence of Fanconi syndrome. weighing 50 kg or more, take one tablet of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet once daily followed by one additional 200 mg per day of efavirenz [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].

Efavirenz. Emtricitabine and Tenofovir disoproxil fumarate is available as tablets. Each tablet contains 600 mg fumarate tablet with either lopinavir/ ritonavir or darunavir and ritonavir and ritonavir divinent, 200 mg of emtricitable and 300 mg of tenofovir disproxil fumarate (tenofovir DF, which is equivalent to 245 mg of tenofovir disproxil). The tablets are pink colored, capsule-shaped, biconvex film capted (telosed with C210 on one sitter site and plan on table site and 5.9 Bone Loss and Mineralization Defect coated, debossed with 'C210'on one side and plain on other side.

- Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is contraindicated in patients with
- Eleviteliz, Entitudante and reindovir disploar furnate table to constant and a provide previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of Efavirenz, Emtricitabine and
- Tenofovir disoproxil fumarate tablet [see Warnings and Precautions (5.2)]. Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].
- **5 WARNINGS AND PRECAUTIONS**

with advanced liver disease or cirrhosis, since posttreatment exacerbation of hepatitis may lead to hepatic

(e.g., Stevens-Jonnson syndrome, Females and Males of Reproductive erythema multiforme, or toxic skin Potential: Pregnancy testing and Incontrolled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV experienced new-onset Hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered in participation of the productive erythema and osteomalacia secondary to proximal renal tubulopathy should be considered in participation of the productive erythema and osteomalacia secondary to proximal renal tubulopathy should be considered in participation of the productive erythema and osteomalacia secondary to proximal renal tubulopathy should be considered in participation of the productive erythema and osteomalacia secondary to proximal renal tubulopathy should be considered in participation of the productive erythema and osteomalacia secondary to proximal renal tubulopathy should be considered in participation erythema eruptions) to efavirenz, a component of Efavirenz, Emtricitabine and Tenofovir eruptions) to efavirenz, Emtricitabine and Tenofovir Efavirenz, Emtricitabine and Tenofovir eruptions) to efavirenz a component of Efavirenz a Grade 4 rash (e.g., erythema multiforme, Stevens-Johnson syndrome) in adult subjects treated with EFV in Coadministration with voriconazole. (4)
 Coadministration with elbasyir/
 Coadministration with elbasyir/
 See 17 for PATIENT COUNSELING
 Counseling the set of **INFORMATION** and **FDA-approved patient Iades**) and, in most subjects continuing inerapy with EFV, rash resolves within 1 month (median duration, 16 days). The discontinuation rate for rash in adult clinical trials was 1.7% (17/1,008). Efavirenz, Emtricitables **Iabeling**. Revised: 12/2020 Efavirenz, Emtricitable and Tenofovir disoproxil fumarate tablet should be discontinued in patients developing 5.11 Lactic Acidosis/Severe Hepatomegaly with Steatosis severe rash associated with blistering, desquamation, mucosal involvement, or fever. Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. For patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome), alternative therapy should be fumarate tablet, alone or in combination with other antiretrovirals. Treatment with Efavirenz, Emtricitabine a onsidered [see Contraindications (4)].

considered [see Contraindications (4)]. Experience with EFV in subjects who discontinued other antiretroviral agents of the NNRTI class is limited. Nineteen subjects who discontinued nevirapine because of rash have been treated with EFV. Nine of these steatosis even in the absence of marked transaminase elevations). ubjects developed mild-to-moderate rash while receiving therapy with EFV, and two of these subjects 5.12 Immune Reconstitution Syndrome liscontinued because of rash.

Rash was reported in 59 of 182 pediatric subjects (32%) treated with EFV [see Adverse Reactions (6.1)]. Two had most oppried in our of point of an endowing the components of Lawrence, Limit and a endowing and endowing (range 3-1,642 days). Prophylaxis with appropriate antihistamines before initiating therapy with Efavirenz, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate furth Emtricitabine and Tenofovir disoproxil fumarate tablet in pediatric patients should be considered.

5.3 Hepatotoxicity Postmarketing cases of hepatitis, including fulminant hepatitis progressing to liver failure requiring hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to ons transplantation or resulting in death, have been reported in patients treated with EFV, a component of Efavirenz, | is more variable, and can occur many months after initiation of treatment. mtricitable and Tenofovir disoproxil fumarate tablet. Reports have included patients with underlying hepatic 5.13 Fat Redistribution disease, including coinfection with hepatitis B or C, and patients without pre-existing hepatic disease or other identifiable risk factors [see Warnings and Precautions (5.1)].

identifiable risk factors [see Warnings and Precautions (5.1)]. Efavirenz, Emtricitable and Tenofovir disoproxil fumarate tablet is not recommended for patients with moderate or severe hepatic impairment. Careful monitoring is recommended for patients with mild hepatic impairment events are currently unknown. A causal relationship has not been established receiving Efavirenz, Emtricitable and Tenofovir disoproxil fumarate tablet [see Adverse Reactions (6.2) and 6 ADVERSE REACTIONS Jse in Specific Populations (8.7)

Administration (2,1)]. Consider discontinuing Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet n patients with persistent elevations of serum transaminases to greater than five times the upper limit of the Rash [see Warnings and Precautions (5.2)]. normal range.

Discontinue Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet if elevation of serum transaminases • Psychiatric Symptoms [see Warnings and Precautions (5.5)]. s accompanied by clinical signs or symptoms of hepatitis or hepatic decompensation [see Adverse Reactions . Nervous System Symptoms [see Warnings and Precautions (5.6)].

5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions **5.4 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Loss of Vitrologic Response Data to Jung Interactions (2.0). 5.6 RNS OF Adverse Reactions of Constructions (2.0). 5.6 RNS OF Adverse Reactions (2.0). 5.6 RNS OF Adverse**

of which may lead to: Loss of therapeutic effect of concomitant drug or Efavirenz, Emtricitabine and Tenofovir disoproxil
 Immune Reconstitution Syndrome [see Warnings and Precautions (5.12)].

fumarate tablet and possible development of resistance.

- Possible clinically significant adverse reaction from greater exposures of Efavirenz. Emtricitable and 6.1 Clinical Trials Experience
- nofovir disoproxil fumarate tablet or concomitant drug. QTc prolongation has been observed with the use of EFV [see Drug Interactions (7.1) and Clinical Pharmacology 12.2)1 Consider alternatives to Efavirenz Emtricitable and Tenofovir disorroxil fumarate tablet when
- ed with a drug with a known risk of Torsade de Pointes or when administered to patients at higher risk of Torsade de Pointes. See Table 3 for steps to prevent or manage these possible and known significant drug interactions, including
- ing recommendations. Consider the potential for drug interactions prior to and during Efavirenz, tricitabine and Tenofovir disoproxil fumarate tablet therapy and review concomitant medications during ontraindications (4), and Drug Interactions (7)].

5.5 Psychiatric Symptoms

Educed potential and the second second second particular in the second s a mean of 1.5 years, the frequency (regardless of causality) of specific serious psychiatric events amon ubijects who received EFV or control regimens, respectively, were: severe depression (2.4%, 0.5%), suicida ideation (0.7%, 0.3%), nonfatal suicide attempts (0.5%, 0%), aggressive behavior (0.4%, 0.5%), paranoid reactions (0.4%, 0.3%), and manic reactions (0.2%, 0.3%). When psychiatric symptoms similar to those note above were combined and evaluated as group in a multifactorial analysis of data from Study Al266006 (006, NCT00002410), a Phase 3 randomized, open-label trial of EFV-containing regimens versus controls in 1,266 subjects (median follow-up 180 weeks, 102 weeks, and 76 weeks for subjects treated with EFV + zidovudine lamivudine, EFV + indinavir, and indinavir + zidovudine + lamivudine, respectively), treatment with EFV was associated with an increase in the occurrence of these selected psychiatric symptoms. Other factors associated with an increase in the occurrence of these psychiatric symptoms were history of injection drug use, psychiatric history, and receipt of psychiatric medication at trial entry; similar associations were observed in both the EFV and control treatment groups. In Study 006, onset of new serious psychiatric symptoms occurred throughou the trial for both EFV-treated and control-treated subjects. One percent of EFV-treated subjects discontinued of interrupted treatment because of one or more of these selected psychiatric symptoms. There have also beer occasional postmarketing reports of death by suicide, delusions, and psychosis-like behavior, although a causa relationship to the use of EEV cannot be determined from these reports. Postmarketing cases of catatonia have also been reported and may be associated with increased EFV exposure. Patients with serious psychiatr adverse experiences should seek immediate medical evaluation to assess the possibility that the symptom

5.6 Nervous System Symptoms

Fifty-three percent (531/1.008) of subjects receiving EFV in controlled trials reported central nervous system symptoms (any grade, regardless of causality) compared to 25% (156/635) of subjects receiving control regimens. These symptoms included dizziness (28.1% of the 1,008 subjects), insomnia (16.3%), impaired oncentration (8.3%), somnolence (7.0%), abnormal dreams (6.2%), and hallucinations (1.2%). Other reported methation (co.vs), someone (co.vs), automatic constraints (co.vs), and matchination (co.vs), someone methation mptoms were exploria, confusion, agitation, amnesia, stupor, anormal thinking, and depersonalization. he majority of these symptoms were mild to moderate (50.7%); symptoms were severe in 2.0% of subjects. Overall, 2.1% of subjects discontinued therapy as a result. These symptoms usually begin during the first or treated with regimens containing EFV and from 3% to 5% in subjects treated with a control regimen. Patients Etavirenz, Emtricitabine, or TDF treated with regimens containing EFV and from 3% to 5% in subjects treated with a control regimen. Facetias should be informed that these common symptoms were likely to improve with continued therapy and were not predictive of subsequent onset of the less frequent psychiatric symptoms [see Warnings and Precautions in clinical trials of EFV, FTC, or TDF in combination with other antiretroviral agents. (5.5)]. Dosing at bedtime may improve the tolerability of these nervous system symptoms [see Dosage and

Analysis of long-term data from Study 006 showed that, beyond 24 weeks of therapy, the incidences of newonset nervous system symptoms among EFV-treated subjects were generally similar to those in the indinavircontaining control arm.

| Late-onset neurotoxicity, including ataxia and encephalopathy (impaired consciousness, confusion psychomotor slowing, psychosis, delirium), may occur months to years after beginning EFV therapy. Some events of late-onset neurotoxicity have occurred in patients with CYP2B6 genetic polymorphisms which are trunartie tablet Prior to or when initiating Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, test patients for symptoms of serious neurologic adverse experiences should be evaluated promptly to assess the possibility treated with EFV 600 mg than in control subjects. Tenofovir disoproxil fumarate tablet is warranted.

disoproxil fumarate tablet is a three- • Redistribution/accumulation of body clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose and urine g Patients who experience central nervous system symptoms such as dizziness, impaired concentration, and/or

New Onset or Worsening Renal Impairment [see Warnings and Precautions (5.7)].

• Lactic Acidosis/Severe Hepatomegaly with Steatosis [see Warnings and Precautions (5.11)].

5.7 New Onset or Worsening Renal Impairment

Hepatotoxicity [see Warnings and Precautions (5.3)].

Embryo-Fetal Toxicity [see Warnings and Precautions (5.8)].

Fat Redistribution [see Warnings and Precautions (5.13)].

fumarate [see Adverse Reactions (6.2)].

clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the

reflect the rates observed in practice.

Clinical Trials in Adult Subjects 934 was an open-label active-controlled trial in which 511 antiretroviral-naive subjects received either C + TDF administered in combination with EFV (N=257) or zidovudine (AZT)/lamivudine (3TC) administered

tion with EFV (N=254). The most common adverse reactions (incidence greater than or equal to 10%, any severity) occurring in Study Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet therapy [see Dosage and Administration (2.5), 934 include diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. Adverse reactions observed in Study 934 were generally consistent with those seen in previous trials of the individual components (Table 1)

Serious psychiatric adverse experiences have been reported in patients treated with EFV, a component of Table 1: Selected Adverse Reactions^a (Grades 2-4) Reported in 25% in Either Treatment Group in Study

934 (0-144 Weeks)						
	FTC+TDF+EFV ^b	AZT/3TC+EFV				
	N=257	N=254				
Fatigue	9%	8%				
Depression	9%	7%				
Nausea	9%	7%				
Diarrhea	9%	5%				
Dizziness	8%	7%				
Upper respiratory tract infections	8%	5%				
Sinusitis	8%	4%				
Rash Event ^c	7%	9%				
Headache	6%	5%				
Insomnia	5%	7%				
Anxiety	5%	4%				
Nasopharyngitis	5%	3%				
Vomiting	2%	5%				

adverse experiences should seek immediate medical evaluation to assess the possibility and the approximation to assess the possibility and the approximation of the approximation of the assess the possibility and the approximation of the assess the possibility and the approximation of the approxima ship to study drug m Weeks 96 to 144 of the trial, subjects received FTC/TDF administered in combination with EFV in place

of FTC+ TDF with EFV event includes rash, exfoliative rash, rash generalized, rash macular, rash maculopapular, rash pruritio and rash vesicular.

In Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no history of virologic failure were randomized to receive Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet or to stay on their baseline regimen. The adverse reactions observed in Study 073 were generally consistent with those seen in Study 334 and those seen with the individual components of Efavirenz. Entricitable and Tenofovir disoproxil prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in subjects

Efavirenz: The most significant adverse reactions observed in subjects treated with EFV were nervous system symptoms [see Warnings and Precautions (5.6)] psychiatric symptoms [see Warnings and Precautions (5.5)]

Selected adverse reactions of moderate-to-severe intensity observed in greater than or equal to 2% of EFVtreated subjects in two controlled clinical trials included pain, impaired concentration, abnormal dreams, ence, anorexia, dyspepsia, abdominal pain, nervousness, and pruritus

Pancreatitis has also been reported, although a causal relationship with EFV has not been establishe 2.1 Testing Prior to Initiation and During Treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil associated with increased EFV levels despite standard dosing of EFV. Patients presenting with signs and

hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic. The mechanism and

Efavirenz: Assessment of adverse reactions is based on three pediatric clinical trials in 182 HIV-1 infected pediatric subjects who received FEV in combination with other antiretroviral agents for a median of 123 weeks The type and frequency of adverse reactions in the three trials were generally similar to that of adult subject with the exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric subject compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash reported in 3% (6/182) of pediatric Emtricitabine and tenofovir are principally eliminated by the kidney; however, EFV is not. Renal impairment.

subjects compared to 0.9% of adults [see Warnings and Precautions (5.2) Emtricitabine: In addition to the adverse reactions reported in adults, anemia and hyperpigmentation wer as been reported with the use of TDF, a component of Efavirenz, Emtricitabine and Tenofovir disoproxil observed in 7% and 32%, respectively, of pediatric subjects who received treatment with FTC in the larger of two open-label, uncontrolled pediatric trials (N=116).

Emtricitabine and Tenofovir disoproxil fumarate tablet is not recommended in patients with moderate or severe observed in clinical trials of TDF in adults *(see Warnings and Precautions (5.9))*.

Laboratory Abnormalities Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs [NSAIDs]) *[see*

Drug Interactions (7,2)) Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in HIV-infected patients with risk factors for renal dysfunction who appeared stable on TDF. Some Study 934 (0-144 Weeks)

5	reported in HIV-infected patients with risk factors for renal dysfunction who appeared stable on TDF. Some patients required hospitalization and renal replacement therapy. Alternatives to NSAIDs should be considered,	Stu	udy 934 (0-144 Weeks)	o in Ennor Froundent aroup in
	if needed, in patients at risk for renal dysfunction.		FTC + TDF + EFV ^a	AZT/3TC + EFV
2	Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness may be		N=257	N=254
;	manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in patients at	Any \geq Grade 3 Laboratory Abnormality	30%	26%
	risk of renal dysfunction.	Fasting Cholesterol (>240 mg/dL)	22%	24%
s t	Discontinue Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. 5.8 Embryo-Fetal Toxicity	Creatine Kinase (M: >990 U/L) (F: >845 U/L)	9%	7%
1	Efavirenz may cause fetal harm when administered during the first trimester of pregnancy. Advise adults	Serum Amylase (>175 U/L)	8%	4%
	and adolescents of childbearing potential who are receiving Efavirenz, Emtricitabine and Tenofovir disoproxil	Alkaline Phosphatase (>550 U/L)	1%	0%
5	fumarate tablet to avoid pregnancy while receiving Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and for 12 weeks after discontinuation [see Dosage and Administration (2.1), Use in Specific Populations (8.1, 8.3)].	AST (M: >180 U/L) (F: >170 U/L)	3%	3%
	5.9 Bone Loss and Mineralization Defects Bone Mineral Density In clinical trials in HIV-1 infected adults, TDF (a component of Efavirenz, Emtricitabine and tenofovir disoproxil	ALT (M: >215 U/L) (F: >170 U/L)	2%	3%
	fumarate tablet) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators. Serum	Hemoglobin (<8.0 mg/dL)	0%	4%
í	parathyroid hormone levels and 1,25 Vitamin D levels were also higher in subjects receiving TDF.	Hyperglycemia (>250 mg/dL)	2%	1%
	Clinical trials evaluating TDF in pediatric and adolescent subjects were conducted. Under normal circumstances,	Hematuria (>75 RBC/HPF)	3%	2%
1	BMD increases rapidly in pediatric patients. In HIV-1 infected subjects aged 2 years to less than 18 years, bone	Glycosuria (≥3+)	<1%	1%
	effects were similar to those observed in adult subjects and suggest increased bone turnover. Total body BMD	Neutrophils (<750/mm ³)	3%	5%
	gain was less in the TDF-treated HIV-1 infected pediatric subjects as compared to the control groups. Similar trends were observed in chronic hepatitis-B infected adolescent subjects aged 12 years to less than 18 years. In	Fasting Triglycerides (>750 mg/dL)	4%	2%
/	all pediatric trials, skeletal growth (height) appeared to be unaffected.	^a From Weeks 96 to 144 of the trial, subjects	received FTC/TDF administered	in combination with EFV in place
1 1 5 - 1 5 5 t , f 1 5 5 , p - 1 5 9 9 - 9	The effects of TDF-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Assessment of BMD shoul be considered for adult and pediatric patients who have a history of pathologic bone fracture or other risk factors for osteoporosis or bone loss. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients. It bone abnormalities are suspected, then appropriate consultation should be obtained. <i>Mineralization Defects</i> Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with TDF use <i>[see Adverse Reactions (6.2)]</i> . Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy. Hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered in patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms while receiving TDF-containing products <i>[see Warnings and Precautions (5.7)]</i> . 5.10 Convulsions have been observed in adult and pediatric patients receiving EFV, generally in the presence of known medical history of seizures. Caution must be taken in any patient with a history of seizures. Patients who are receiving concomitant anticonvulsant medications primarily metabolized by the liver, such as phenytoin and phenobarbital, may require periodic monitoring of plasma levels <i>[see Drug Interactions (7.3)]</i> . 5.11 Lactic Acidosis /Severe Hepatomegaly with Steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including TDA erf. C, components of Efavirenz, Emtricitabine and tenofovir disoproxil fumarate tablet, alone or in combination with other antiretrovirals. Treatment with Efavirenz, Emtricitabine and tenofovir disoproxil fumarate tablet should be suspended in any patient with develops clinical or laborato	of FTC + TDF with EFV. Laboratory abnormalities observed in Study (<i>Hepatic Events</i> : In Study 934, 19 subjects tre fixed-dose zidovudine/lamivudine were hepati coinfected subjects, one subject (1/19) in the than five times ULN through 144 weeks. In ti elevations in transaminases to greater than fi subject discontinued from the trial due to hep 6.2 Postmarketing Experience The following adverse reactions have been postmarketing reactions are reported volunta reliably estimate their frequency or establish Efavirenz: Cardiac Disorders Palpitations Ear and Labyrinth Disorders Tinnitus, vertigo Endocrine Disorders Gynecomastia Eye Disorders Abnormal vision Gastrointestinal Disorders	ated with EFV, FTC, and TDF and tis B surface antigen or hepatitis EFV, FTC, and TDF arm had eleva te fixed-does zidovudine/lamivud ve times ULN through 144 weeks patobiliary disorders [see Warnin identified during postapproval u rily from a population of uncertai	20 subjects treated with EFV and C antibody positive. Among these titions in transaminases to greater line arm, two subjects (2/20) had s. No HBV and/or HCV coinfected gs and Precautions (5.3)]. se of EFV, FTC, or TDF. Because n size, it is not always possible to
	5.12 Immune Reconstitution Syndrome	General Disorders and Administration Site Co	anditions	
	Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy,	Asthenia	manuona	
)	including the components of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as <i>Mycobacterium avium</i> infection,	<i>Hepatobiliary Disorders</i> Hepatic enzyme increase, hepatic failure, hep	atitis	
,	cytomegalovirus, <i>Pneumocystis jirovecii</i> pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.	Immune System Disorders Allergic reactions		
,	Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.	Metabolism and Nutrition Disorders Redistribution/accumulation of body fat [/ hypertriglyceridemia	see Warnings and Precautions	(5.13)], hypercholesterolemia,
-	5.13 Fat Redistribution Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump),	Musculoskeletal and Connective Tissue Disor Arthralgia, myalgia, myopathy	rders	
e t 4	peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance," has been observed in patients receiving antiretroviral therapy, including EFV. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.	Nervous System Disorders Abnormal coordination, ataxia, encephalopath hypoesthesia, paresthesia, neuropathy, tremo		alance disturbances, convulsions,
1	6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling: • Severe Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and HBV [see Warnings and Description (C1)]	Psychiatric Disorders Aggressive reactions, agitation, delusions, e catatonia	emotional lability, mania, neuros	is, paranoia, psychosis, suicide,
L	Precautions (5.1)].	Description Theory is and Medical biographics		

Respiratory, Thoracic and Mediastinal Disorders Skin and Subcutaneous Tissue Disorders Flushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome Emtricitabine: No postmarketing adverse reactions have been identified for inclusion in this section. Tenofovir DF: Immune System Disorders Allergic reaction, including angioedema Metabolism and Nutrition Disorders

Lactic acidosis, hypokalemia, hypophosphatemia

clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not

Pancreatitis, increased amylase, abdominal pain enatohiliary Disorde

Respiratory, Thoracic, and Mediastinal Disorders

Hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT, gamma GT)

Skin and Subcutaneous Tissue Disorders

keletal and Connective Tissue Disorder Rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy

Renal and Urinary Disorder

Acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, renal insufficiency, increase creatinine, proteinuria, polyuria

General Disorders and Administration Site Condition

The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia, hypokalemia, muscular weakness, myopathy hypophosphatemia

7 DRUG INTERACTIONS

7.1 Efavirenz

iz has been shown *in vivo* to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with EFV Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the

clearance of EFV, resulting in lowered plasma concentrations [see Dosage and Administration (2.2)]. There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. QTc prolongation has been observed with the use of EFV [see Clinica Pharmacology (12.2)). Consider alternatives to Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate table when coadministered with a drug with a known risk of Torsade de Pointes.

7.2 Drugs Affecting Renal Function

FTC and tendovir are primarily eliminated by the kidneys [see Clinical Pharmacology (12.3)]. Coadministration of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with drugs that are eliminated by active tubular secretion may increase concentrations of FTC, tenofovir, and/or the coadministered drug. Some examples include, but are not limited to, acyclovir, adefovir dipivoxil, citofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.7)]. Drugs that decrease renal function may increase concentrations of FTC and/or tenofovi 7 3 Established and Potentially Significant Interactions

Other important drug interaction information for Efavirenz, Emtricitabine and Tenofovir disoproxil fumarat tablet is summarized in Table 3. The drug interactions described are based on trials conducted with either Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, the components of Efavirenz, Emtricitab and Tenofovir disoproxil fumarate tablet (EFV, FTC, or TDF) as individual agents, or are potential drug interactions [see Clinical Pharmacology (12.3)].

Concomitant Drug Class: Drug Name	Effect	Clinical Comment
HIV antiviral agents	L atage - and	Condministration of shares in the state
Protease inhibitor: atazanavir	↓ atazanavir ↑ tenofovir	Coadministration of atazanavir with Efavire Emtricitabine and Tenofovir disoproxil fumarate table not recommended. The combined effect of EFV plus 1 on atazanavir plasma concentrations is not known. Th are insufficient data to support dosing recommendati for atazanavir or atazanavir/ritonavir in combination w Efavirenz, Emtricitabine and Tenofovir disoproxil fumar tablet.
Protease inhibitor: fosamprenavir calcium	↓ amprenavir	Fosamprenavir (unboosted): Appropriate doses fosamprenavir and Etavirenz, Emtricitabine and Tenofo disoproxil fumarate tablet with respect to safety a efficacy have not been established. Fosamprenavir/ritonavir: An additional 100 mg/
		(300 mg total) of ritonavir is recommended wh Efavirenz, Emtricitabine and Tenofovir disoproxil fumar tablet is administered with fosamprenavir/ritonavir or daily. No change in the ritonavir dose is required wh Efavirenz, Emtricitabine and Tenofovir disoproxil fumar tablet is administered with fosamprenavir plus ritona twice daily.
Protease inhibitor: indinavir	↓ indinavir	The optimal dose of indinavir, when given in combinat with EFV, is not known. Increasing the indinavir di to 1000 mg every 8 hours does not compensate for increased indinavir metabolism due to EFV.
Protease inhibitor: darunavir/ritonavir	↑ tenofovir	Monitor patients receiving Efavirenz, Emtricitabine a Tenofovir disoproxil fumarate tablet concomitantly w ritonavir-boosted darunavir for TDF-associated adve reactions. Discontinue Efavirenz, Emtricitabine a Tenofovir disoproxil fumarate tablet in patients w develop TDF-associated adverse reactions.
lopinavir/ritonavir	↓ lopinavir ↑ tenofovir	Do not use once daily administration of lopinavir/ritonar Dose increase of lopinavir/ritonavir is recommended all patients when coadministered with EFV. Refer to Full Prescribing Information for lopinavir/ritonavir guidance on coadministration with EFV-or tenofor containing regimens, such as Efavirenz, Entricitaba and Tenofovir disoproxil fumarate tablet. Patients sho be monitored for tenofovir-associated adverse reactio Discontinue Efavirenz, Entricitabine and Tenofor disoproxil fumarate tablet in patients who develop TI associated adverse reactions.
Protease inhibitor: ritonavir	↑ ritonavir ↑ efavirenz	When ritonavir 500 mg every 12 hours v coadministered with EFV 600 mg once daily, combination was associated with a higher frequency adverse clinical experiences (e.g., dizziness, naus paresthesia) and laboratory abnormalities (elevated li enzymes). Monitoring of liver enzymes is recommend when Efavirenz, Emtricitabine and Tenofovir disopri fumarate tablet is used in combination with ritonavir.
Protease inhibitor: saquinavir	↓ saquinavir	Appropriate doses of the combination of EFV a saquinavir/ritonavir with respect to safety and effici- have not been established.
CCR5 co-receptor antagonist: maraviroc	↓ maraviroc	Refer to the full prescribing information for maravi for guidance on coadministration with Efavire Emtricitabine and Tenofovir disoproxil fumarate tablet.
NRTI: didanosine	↑ didanosine	Patients receiving Efavirenz, Emtricitabine and Tenofo disoproxil fumarate tablet and didanosine should monitored closely for didanosine-associated adve reactions. Discontinue didanosine in patients w develop didanosine-associated adverse reactions. Hig didanosine concentrations could potentiate didanosi associated adverse reactions, including pancreatitis, a neuropathy. Suppression of CD4+ cell counts has be observed in patients receiving TDF with didanosine 4 mg daily.
		In patients weighing greater than 60 kg, reduce didanosine dose to 250 mg when it is coadministered w Efavirenz, Emtricitabine and Tenofovir disoproxil fumar tablet. In patients weighing less than 60 kg, reduce i didanosine dose to 200 mg when it is coadministered w Efavirenz, Emtricitabine and Tenofovir disoproxil fumar tablet. When coadministered, Efavirenz, Emtricitabine an Tenofovir disoproxil fumarate tablet and Videx EC may taken under fasted conditions or with a light meal (let than 400 kcal, 20% fat)
NNRTI: Other NNRTIs	\uparrow or \downarrow efavirenz and/or NNRTI	Combining two NNRTIs has not been shown to beneficial. Efavirenz, Entricitable and Tenofe disoproxil fumarate tablet contains EFV and should not coadministered with other NNRTIs.
Integrase strand transfer inhibitor: raltegravir	↓ raltegravir	The clinical significance of this interaction has not be directly assessed.
Hepatitis C antiviral agents	bocoprovir	Diacma traugh concentrations of become
boceprevir	↓ boceprevir	Plasma trough concentrations of boceprevir w decreased when boceprevir was coadministered w EFV, which may result in loss of therapeutic effect. T combination should be avoided.
elbasvir/grazoprevir	↓ elbasvir ↓ grazoprevir	Coadministration of Efavirenz, Emtricitabine and Tenofc disoproxil fumarate tablet with elbasvir/grazoprevir contraindicated [see Contraindications (4)] becau it may lead to loss of virologic response to elbasv grazoprevir.
glecaprevir/pibrentasvir	↓ glecaprevir ↓ pibrentasvir	Coadministration of Efavirenz, Emtricitabine and Tenofo disoproxil fumarate tablet is not recommended becan it may lead to reduced therapeutic effect of glecapre pibrentasvir.
ledipasvir/sofosbuvir	↑ tenofovir	Patients receiving Efavirenz, Emtricitabine and Tenofo disoproxil fumarate tablet and HARVONI [®] (ledipas sofosbuvir) concomitantly should be monitored adverse reactions associated with TDF.
simeprevir	↓ simeprevir ↔ efavirenz	Concomitant administration of simeprevir with EFV is recommended because it may result in loss of theraper effect of simeprevir.

Concomitant Drug Class: Drug Name	Effect	Clinical Comment
sofosbuvir/velpatasvir sofosbuvir/velpatasvir/ voxilaprevir	↑ tenofovir ↓ velpatasvir ↓ voxilaprevir	Coadministration of EFV-containing regimens and EPCLUSA® (sofosbuvir/velpatasvir) or VOSEVI® (sofosbuvir/velpatasvir/voxilaprevir) is not recommended.
Other agents Anticoagulant: warfarin	↑ or \downarrow warfarin	Plasma concentrations and effects potentially increased or decreased by EFV.
Anticonvulsants: carbamazepine	↓ carbamazepine ↓ efavirenz	There are insufficient data to make a dose recommendation for Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Alternative anticonvulsant treatment should be used.
phenytoin phenobarbital	↓ anticonvulsant ↓ efavirenz	Potential for reduction in anticonvulsant and/or EFV plasma levels; periodic monitoring of anticonvulsant plasma levels should be conducted.
Antidepressants: bupropion	↓ bupropion	The effect of EFV on bupropion exposure is thought to be due to the induction of bupropion metabolism. Increases in bupropion dosage should be guided by clinical response, but the maximum recommended dose of bupropion should not be exceeded.
sertraline	↓ sertraline	Increases in sertraline dose should be guided by clinical response.
Antifungals: itraconazole	↓ itraconazole ↓ hydroxy- itraconazole	Since no dose recommendation for itraconazole can be made, alternative antifungal treatment should be considered.
ketoconazole	↓ ketoconazole	Drug interaction trials with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and ketoconazole have not been conducted. Efavirenz has the potential to decrease plasma concentrations of ketoconazole.
posaconazole	\downarrow posaconazole	Avoid concomitant use unless the benefit outweighs the risks.
voriconazole	↓ voriconazole ↑ efavirenz	Coadministration of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with voriconazole is contraindicated [see Contraindications (4)] because it may lead to reduced therapeutic effect of voriconazole and increased risk of EFV-associated adverse reactions
Anti-infective: clarithromycin	↓ clarithromycin ↑ 14-0H metabolite	Consider alternatives to macrolide antibiotics because of the risk of QT interval prolongation.
Antimycobacterial: rifabutin	↓ rifabutin	Increase daily dose of rifabutin by 50%. Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
rifampin	↓ efavirenz	If Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is coadministered with rifampin to patients weighing 50 kg or more, an additional 200 mg/day of EFV is recommended.
Antimalarials: artemether/ lumefantrine	↓ artemether ↓ dihydroartemisinin ↓ lumefantrine	Consider alternatives to artemether/lumefantrine because of the risk of QT interval prolongation [see Warnings and preservices (5.4)]
atovaquone/proguanil	↓ atovaquone ↓ proguanil	Precautions (5.4)]. Concomitant administration of atovaquone/proguanil with Efavirenz. Emtricitabine and Tenofovir discoroxil fumarate
Coloium obannal blookara	↓ diltiazem	tablet is not recommended.
Calcium channel blockers: diltiazem	↓ diitiazem ↓ desacetyl diltiazem	Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem). No dose adjustment of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is necessary when administered with diltiazem.
	↓ N-monodes- methyl diltiazem	
Others eg, felodipine, nicardipine, nifedipine, verapamil	↓ calcium channel blocker	No data are available on the potential interactions of EFV with other calcium channel blockers that are substrates of CVP3A. The potential exists for reduction in plasma concentrations of the calcium channel blocker. Dose adjustments should be guided by clinical response (refer to the full prescribing information for the calcium channel blocker).
HMG-CoA reductase inhibitors: atorvastatin pravastatin simvastatin	↓ atorvastatin ↓ pravastatin ↓ simvastatin	Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased with EFV. Consult the Ful Prescribing Information for the HMG-CoA reductase inhibitor for guidance on individualizing the dose.
Hormonal contraceptives: Oral: ethinyl estradiol/ norgestimate	↓ active metabolites of norgestimate	A reliable method of barrier contraception must be used in addition to hormonal contraceptives. Efavirenz had no effect on ethinyl estradiol concentrations, but progestin levels (norelgestromin and levonorgestrel) were markedly decreased. No effect of ethinyl estradiol/norgestimate on EFV plasma concentrations was observed.
Implant: etonogestrel	↓ etonogestrel	A reliable method of barrier contraception must be used in addition to hormonal contraceptives. Decreased exposure of etonogestrel may be expected. There have been postmarketing reports of contraceptive failure with etonogestrel in EFV-exposed patients.
Immunosuppressants: cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A	↓ immuno- suppressant	Decreased exposure of the immunosuppressant may be expected due to CYP3A induction by EFV. These immunosuppressants are not anticipated to affect exposure of EFV. Dose adjustments of the immunosuppressant may be required. Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil tumarate tablet.
Narcotic analgesic: methadone	↓ methadone	Coadministration of EFV in HIV-1 infected individuals with a history of injection drug use resulted in signs of opiate withdrawal. Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms. Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Antiretroviral Pregnancy Registry registry that monitors pregnancy outcomes in adults and adolescents exposed b Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet during pregnancy. Health are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at (800) 258-4263 Risk Summarv

here are retrospective case reports of neural tube defects in infants whose mothers were exposed to FFVontaining regimens in the first trimester of pre sufficient to adequately assess this risk. Although a causal relationship has not been established between osure to EFV in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose (see Data). In addition, fetal and embryonic toxicities occurred in rats at a dose 10 times less than the human exposure at the recommended clinical huma se (RHD) of EFV. Because of the potential risk of neural tube defects, EFV is not recommended for use in the first trimester of pregnancy. Avoid pregnancy while receiving Efavirenz, Emtricitabine and Tenofovir disoproxi fumarate tablet and for 12 weeks after discontinuation. Advise pregnant patients of the potential risk to a fetus.

Available data from the APR show no increase in the overall risk of major birth defects for EFV. FTC, or TDF compared with the background rate for major birth defects of 2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) (see Data)

The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15- 20%. The background risk of major birth defects and miscarriage for the indicated population is unknown. The APR uses the MACDP as the U.S. reference population for birth defects in the general population. The MACDP evaluates mothers and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks' gestation. In animal reproduction studies, no adverse developmental effects were observed when FTC and TDF were

administered separately at doses/exposures \geq 60 (FrC), \geq 14 (TDF) and 2.7 (tenofovir) times those at the RHD of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet (*see Data*). Human Data Efavirenz: There are retrospective postmarketing reports of findings consistent with neural tube defects.

icluding meningomyelocele, all in infants of mot V-containing regimens in the first trimester Based on prospective reports to the APR of 1,217 exposures to EFV-containing regimens during pregnance resulting in live births (including over 1.023 live births exposed in the first trimester and 194 exposed in the second/third trimester), there was no increase in overall birth defects with FEV compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of birth defects in live births was 2.3% (95% Cl: 1.5% to 3.5%) with first trimester exposure to EFV-containing regimens, and 1.5% (95% CI: 0.3% to 4.5%) with the second/third trimester exposure to FFV-containing regimens. One of these prospectively reported detects with first-trimester exposure was a neural tube detect. A single case of anophthalmia with first-trimester exposure to EFV has also been prospectively reported. This case also included severe oblique facial clefts and amniotic banding, which have a known association with anophthalmia.

Emtricitabine: Based on prospective reports from the APR of 4.005 exposures to FTC-containing regimens during pregnancy resulting in live births (including 2,785 exposed in the first trimester and 1,220 exposed in the second/third trimester), there was no increase in overall major birth defects with FTC compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of birth defects in live births was 2.4% (95% CI: 1.9% to 3.1%) with first trimester exposure to FTC-containing regimens and 2.3% (95% CI: 1.5% to 3.3%) with the second/third trimester exposure to FTC-containing regimens. Tenofovir DF: Based on prospective reports from the APR of 5.105 exposures to TDF-containing regimens

uning pregnancy resulting in live births (including 3,535 exposed in the first trimester and 1,570 exposed in the second/third trimester), there was no increase in overall major birth defects with TDF compared with the background birth defect rate of 2.7% in the U.S. reference population of the MACDP. The prevalence of birth defects in live births was 2.3% (95% CI: 1.8% to 2.9%) with first trimester exposure to TDF-containing regimens, and 2.2% (95% CI: 1.6% to 3.1%) with the second/third trimester exposure to TDF-containing

Patient Information

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate (e FAV e renz, em trye SYE ta been, & ten OF oh vir dye soe PROX il FUE ma rate)

What is the most important information I should know about Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet can cause serious side effects, including:

 Worsening of hepatitis B virus (HBV) infection. Your healthcare provider will test you for HBV before starting treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. If you have HBV infection and take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, your HBV may get worse (flare-up) if you stop taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. A "flare-up" is when your HBV infection suddenly returns in a worse way than before.

- Do not stop taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet without first talking with your healthcare provider
- Do not run out of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Refill your prescription or talk to your healthcare provider before your Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is all gone
- If you stop taking Efavirenz. Emtricitabine and Tenofovir disoproxil fumarate tablet, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection, or give you a medication to treat hepatitis B. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet

For more information about side effects see the section, "What are the possible side effects of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?'

What is Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is a prescription medicine that contains efavirenz, emtricitabine, and tenofovir disoproxil fumarate combined in 1 tablet. Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is used alone as a complete regimen, or in combination with other anti-HIV-1 medicines to treat people with HIV-1 infection who weigh at least 88 lbs (40 kg). It is not known if Efavirenz. Emtricitabine and Tenofovir disoproxil fumarate tablet is safe and effective for use in children with HIV-1 infection who weigh less than 88 lbs (40 kg).

Who should not take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

Do not take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet if you:

- are allergic to efavirenz
- take the medicine called voriconazole, elbasvir or grazoprevir
- Ask your healthcare provider if you are not sure if you take any of these medicines.

Before taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, tell your healthcare provider about all of your medical conditions, including if you:

- have liver problems, including hepatitis B or C virus infection
- have heart problems
- have or have had mental problems
- have a history of drug or alcohol abuse
- have nervous system problems have kidney problems or receive kidney dialysis treatment
- have bone problems
- have had seizures or take medicines used to treat seizures

 are pregnant or plan to become pregnant. Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet can harm your unborn baby. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. You should not become pregnant during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and for 12 weeks after stopping treatment. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.

- Females who are able to become pregnant should use 2 effective forms of birth control (contraception) during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and for 12 weeks after stopping treatment.
- A barrier form of birth control should always be used along with another type of birth control. Barrier forms of birth control may include condoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.
- Birth control methods that contain the hormone progesterone such as birth control pills, injections vaginal rings, or implants, may not work as well while taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- Talk to your healthcare provider about birth control methods that may be right for you during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- **Pregnancy Registry:** There is a pregnancy registry for women who take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry. • are breastfeeding or plan to breastfeed. Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet can pass
- into your breast milk. Do not breastfeed because of the risk of passing HIV-1 to your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and some medicines may interact with each other causing serious side effects.

You can ask your healthcare provider or pharmacist for a list of medicines that interact with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Do not start a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with other medicines.

How should I take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet? • Take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet exactly as your healthcare provider tells

vou to If you take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with other medicines used to treat HIV-1, your healthcare provider will tell you what medicines to take and how to take them.

• Take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet 1 time each day on an empty stomach. You should take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet at the same time each day.

 Taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet at bedtime may make some side effects less bothersome

• Do not miss a dose of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Missing a dose lowers the amount of medicine in your blood. Refill your Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet prescription before you run out of medicine.

• Do not change your Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet dose or stop taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet without first talking with your healthcare provider. Stay under a healthcare provider's care during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet

 If you take too much Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet, call your healthcare provider or got to the nearest hospital emergency room right away.

What should I avoid while taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

 Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet can cause dizziness, impaired concentration and drowsiness. If you have these symptoms, do not drive a car, use heavy machinery, or do anything that requires you to be alert.

What are the possible side effects of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

- Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet may cause serious side effects, including:
- See "What is the most important information I should know about Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?'
- Rash. Rash is a serious side effect but may also be common. Rashes will usually go away without any change in your treatment. Tell your healthcare provider right away if you develop a rash during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomacharea pain.
- Mental problems. Serious mental problems including severe depression, suicidal thoughts and actions, aggressive behavior, delusions, catatonia, and paranoid and manic reactions have happened in people who take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. These mental health problems may happen more often in people who have a history of mental problems or drug use, or who take medicines to treat mental problems. Tell your healthcare provider right away if you develop serious mental problems during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- Nervous system problems. Nervous system problems usually begin during the first or second day of treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and usually go away after 2 to 4 weeks of treatment. Some symptoms may occur months to years after beginning Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet therapy. These symptoms may become more severe if you drink alcohol or take mood altering (street) drugs while taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Tell your healthcare provider right away if you develop nervous system problems during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Symptoms of nervous system problems may include:
- problems sleeping problems concentrating excessive sleepiness or difficulty awakening • abnormal dreams • seeing or hearing things that are not real (hallucinations)

confusion

memory problems

• lack of coordination or difficulty with balance

- unusually happy mood
- agitation
- thought problems

dizziness

slow thoughts and physical movement

If you have dizziness, trouble concentrating or sleepiness, do not drive a car, use machinery, or do anything that needs vou to be alert.

- New or worse kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys before you start and during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Your healthcare provider may tell you to stop taking Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet if you develop new or worse kidney problems during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- **Bone problems** can happen in some people who take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Bone problems include bone pain or softening or thinning of bones, which may lead to fractures. Your healthcare provider may need to do tests to check your bones.
- Seizures. Your healthcare provider may do blood tests during treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet if you take certain medicines used to prevent seizures.
- Too much lactic acid in your blood (lactic acidosis). Too much lactic acid is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you develop any of these symptoms:
- weakness or being more tired than usual
 fast or abnormal heartbeat
- being short of breath or fast breathing unusual muscle pain cold or blue hands and feet
 - stomach pain with nausea and vomiting
 - feel dizzy or lightheaded

abnormal dreams

- Changes in your immune system (Immune Reconstitution Syndrome) can happen when an HIV-1 infected person starts taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you develop any new symptoms after starting treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet.
- Changes in body fat. Changes in body fat distribution or accumulation have happened in some people taking HIV-1 medicines, including an increased amount of fat in the upper back and neck ("buffalo hump"), in the breasts, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and longterm health effects of these body fat changes are not known.

The most common side effects of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet include:

•	diarrhea	•	nausea
•	tiredness	•	headache
•	dizziness	•	depression

- depression
- problems sleeping
- rash

These are not all the possible side effects of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

 Store Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet at room temperature 77°F (25°C). • Keep Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet in its original container and keep the

container tightly closed. Keep Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and all other medicines out of reach of children.

General information about the safe and effective use of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet for a condition for which it was not prescribed. Do not give Efavirenz. Emtricitabine and Tenofovir disoproxil fumarate tablet to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet that is written for health professionals.

What are the ingredients of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet?

Active Ingredients: efavirenz, emtricitabine, and tenofovir disoproxil fumarate

Inactive Ingredients: Croscarmellose sodium, hydroxypropyl cellulose, hypromellose, isopropyl alcohol, microcrystalline cellulose, magnesium stearate, red iron oxide, sodium lauryl sulfate. The tablets are film-coated with a coating material opadry AMB 80W54485 pink containing polyvinyl alcohol-part, hydrolyzed, titanium dioxide, talc, lecithin (soya), xanthan gum, iron oxide yellow, iron oxide red and opadry AMB 80W56843 brown containing polyvinyl alcohol-part, hydrolyzed, titanium dioxide, talc, lecithin (soya), xanthan gum, iron oxide red.

Disclaimer: Other brands listed are the registered trademarks of their respective owners and are not trademarks of Exelan Pharmaceuticals. Inc.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Manufactured by: Genvion Corporation Winnipeg, Manitoba R2J 4K2 Canada Manufactured for: Exelan Pharmaceuticals, Inc Boca Raton, FL 33432 Revised: 12/2020

PI009 Rev 02.indd 2

Efavirenz Effects of EFV on embryo-fetal development have been studied in three nonclinical species cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60 mg/kg/day was administered to pregnant emales throughout pregnancy (gestation Days 20 through 150). The maternal systemic drug exposures (AUC) times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposite set of the exposites of 20 fetuses/infants had one or more malformations; there were no times the exposite set of the exposites of the exposites of the exposite set of the exposites of the exposite set of the exposites of the exposite set of the exposites of the exposites of the exposites of the exposite set of the exposites of the exposites of the exposite set of the exposites of the exposites of the exposite set of the exposites of the exposites of the exposite set of the exposites of the exposite set of the exposites of the exposites of the exposite set of the exposite set of the exposites of the exposite set of the exposites of the exposite set of the exposite set of the exposite set of the exposite set of the exposites of the exposite set of the exposit malformed fetuses or infants from placebo-treated mothers. The malformations that occurred in these three monkey fetuses included anencephaly and unilateral anophthalmia in one fetus, microphthalmia in a second, and cleft palate in the third. There was no NOAEL (no observable adverse effect level) established for this study because only one dosage was evaluated. In rats, EFV was administered either during organogenesis (gestation dose for 14 days [see Warnings and Precautions (5.4)]. Days 7 to 18) or from gestation Day 7 through lactation Day 21 at 50, 100, or 200 mg/kg/day. Administration of 200 mg/kg/day in rats was associated with an increase in the incidence of early resorptions, and doses 100 mg/kg/day and greater were associated with early neonatal mortality. The AUC at the NOAEL (50 mg/kg/ day) in this rat study was 0.1 times that in humans at the RHD. Drug concentrations in the milk on lactation Day 10 were approximately 8 times higher than those in maternal plasma. In pregnant rabbits, EFV was neither embryo lethal nor teratogenic when administered at doses of 25, 50, and 75 mg/kg/day over the period of Days 6 through 18). The AUC at the NOAEL (75 mg/kg/day) in rabbits was 0.4 times hat in humans at the RHD

Emtricitabine: FTC was administered orally to pregnant mice (at 0, 250, 500, or 1,000 mg/kg/day), and rabbits Lather transmission of the second with FTC in mice at exposures (AUC) approximately 60 times higher and in rabbits at approximately 120 times higher than human exposures (AbC) approximately ob times higher and in rabbins at approximately 120 times higher than human exposures at the RHD. In a pre/postnatal development study in mice, FTC was administered orally at doses up to 1000 mg/kg/day; no significant adverse effects directly related to drug were observed in the offspring exposed daily from before birth (in utero) through sexual maturity at daily exposures (AUC) of ately 60 times higher than human exposures at the RHD

fovir DF: TDF was administered orally to pregnant rats (at 0, 50, 150, or 450 mg/kg/day) and rabbits (at 0, 30, 100, or 300 mg/kg/day) through organogenesis (on gestation days 7 through 17, and 6 through 18, to so in the second sec up to 19 times the RHD based on body surface area comparisons. In a pre/postnatal development study in rats, inistered orally through lactation at doses up to 600 mg/kg/day; no adverse effects were observe in the offspring at tenofovir exposures of approximately 2.7 times higher than human exposures at the RHD.

8.2 Lactation Risk Summary

The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their fasted state, maximum serum concentrations (Cmax) were achieved in 1.0 ± 0.4 hrs (mean ± SD) and Cmax and infants to avoid risking postnatal transmission of HIV-

Based on limited published data, EFV, FTC, and tenofovir have been shown to be present in human breast milk. Based on immed published data, EFV, FTC, and tenotovir nave been shown to be present in numan preast milk. It is not known if the components of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet affect milk production or being and the binding is independent of concentration over the range of 0.01-25 µg/mL. Approximately 70-80% of the intravenous dose of tenofovir is recovered as unchanged drug in the urine. Tenofovir is milk production or have effects on the breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative infants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse reactions in a dults with normal renal function of 243 ± 33 mL/min (mean ± SD). Following a single oral dose, the terminal breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are receiving Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet

8.3 Females and Males of Reproductive Potential Pregnancy Testing

Perform pregnancy testing in adults and adolescents of childbearing potential before initiation of Efavirenz, mtricitabine and Tenofovir disoproxil fumarate tablet because of potential risk of neural tube defects [see Use in Specific Populations (8.1)

Advise adults and adolescents of childbearing potential to use effective contraception during treatment with Specific Populations tavienz, Entricitabine and Tenofovir disoproxil fumarate tablet and for 12 weeks after discontinuing Efavienz, mtricitabine and Tenofovir disoproxil fumarate tablet due to the long half-life of EFV, a component of Efavirenz, tricitabine and Tenofovir disoproxil fumarate tablet . Hormonal methods that contain progesterone may have studied. ased effectiveness Always use barrier contraception in combination with other methods of contraception Emtricitabine: No pharmacokinetic differences due to race have been identified following the administration [see Drug Interactions (7.1, 7.3)].

8.4 Pediatric Use

The effectiveness and safety of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet as a complete regimen for the treatment of HIV-1 infection was established in pediatric patients with body weight greater than or equal to 40 kg [see Dosage and Administration (2.2)]. Use of Efavirenz, Emtricitabine and Tenofovir roxil fumarate tablet in this age group is supported by adequate and well-controlled studies of Efaviren. citabine and Tenofovir disoproxil fumarate tablet in adults with HIV-1 infection and data from pediatri studies of the individual components of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet (EFV,

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet should only be administered to pediate patients with a body weight greater than or equal to 40 kg Because Efavirenz Emtricitabine and Tenofovir roxil fumarate tablet is a fixed-dose combination tablet, the dose of Elavienz, Entricitable and Tenofovir roxil fumarate tablet is a fixed-dose combination tablet, the dose of Elavienz, Entricitable and Tenofovir roxil fumarate tablet cannot be adjusted for patients of lower weight [see Warnings and Precautions (5.2, 5.9), Adverse Reactions (6.1), and Clinical Pharmacology (12.3)]. 8.5 Geriatric Use

concomitant disease or other drug therapy

8.6 Renal Impairment

Because Efavirenz, Emtricitabine and Tenofovir disporoxil fumarate tablet is a fixed-dose combination, and cannot be dose adjusted, it is not recommended in patients with moderate or severe renal impai creatinine clearance below 50 mL/min) [see Dosage and Administration (2.3), Warnings and Precautions (5.7)]. 8.7 Henatic Impairment

, Emtricitabine and Tenofovir disoproxil fumarate tablet is not recommended for patients with moderate or severe hepatic impairment because there are insufficient data to determine an appropriate dose. Patients with mild hepatic impairment may be treated with Efavirenz. Emtricitabine and Tenofovir disoproxil fumarate tablet at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation and the proved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because of the extensive cytochrome P450-mediated metabolism of EFV and limitation at the approved dose. Because at the approved at the appro Emtricitabine and Tenofovir disoproxil fumarate tablet to these patients [see Dosage and Administration (2.4)] Varnings and Precautions (5.3), and Clinical Pharmacology (12.3)]. **10 OVERDOSAGE**

f overdose occurs, the patient should be monitored for evidence of toxicity, and standard supportive treatment

ied as necessary. Administration of activated charcoal may be used to aid removal of unabsorbed EFV. Hemodialysis can remove both FTC and TDF (refer to detailed information below) but is unlikely to significantly remove EFV from the blood.

Efavirenz: Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.

eriod starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether FTC can be removed by peritoneal dialysis.


Tenofovir DF: Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of TDF, a 4-hour hemodialysis session removed approximately 10% of the administered tenofovir dose

11 DESCRIPTION

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is a fixed-dose combination tablet containing EFV, FTC, and TDF. EFV is a non-nucleoside reverse transcriptase inhibitor (NNRTI). FTC is a synthetic nucleoside analog of cytidine. TDF, which is converted *in vivo* to tenofovir, is an acyclic nucleoside phosphonate nucleotide) analog of adenosine 5'-monophosphate

irenz, Emtricitabine and Tenofovir disoproxil fumarate tablets are for oral administration. Each tablet not be expected based on NRTIs elimination pathways. contains 600 mg of EFV, 200 mg of FTC, and 300 mg of TDF (equivalent to 245 mg of tenofovir disoproxil) as active ingredients. The tablets include the following inactive ingredients: Croscarmellose sodium, hydroxypropyl cellulose, hypromellose, isopropyl alcohol, microcrystalline cellulose, magnesium stearate, red iron oxide, sodium lauryl sulfate. The tablets are film-coated with a coating material opadry AMB 80W54485 pink containing oolyvinyl alcohol-part, hydrolyzed, titanium dioxide, taic, lecithin (soya), xanthan gum, iron oxide yellow, iron oxide red and opadry AMB 80W56843 brown containing polyvinyl alcohol-part, hydrolyzed, titanium dioxide, lecithin (sova), xanthan gum, iron oxide red. Efavirenz: EFV is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1.4-dihydro-4-(trifluoromethyl)-

2H-3,1-benzoxazin-2-one. Its molecular formula is $C_{14}H_9CIF_3NO_2$ and its structural formula is:




Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble

in water (less than 10 µg/mL) Emtricitabine: The chemical name of FTC is 5-fluoro-1-(2R,5S)-[2-(hydroxymethyl)-1.3-oxathiolan-5-yll ytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which differs from other cytidine analogs in that it has a fluorine in the 5-position

It has a molecular formula of C.H., FNLO, S and a molecular weight of 247,24. It has the following structural

$$H_2N$$
 H_2N H_2N

Tenofovir DF: TDF is a fumaric acid salt of the *bis*-isopropoxycarbonyloxymethyl ester derivative of tenofovir. The chemical name of TDF is 9-[(B)-2][bis][(isoprorarbonyl)oxyl-methoxyl phosphi adenine fumarate (1:1). It has a molecular formula of $C_{19}H_{30}N_3O_{10}P \cdot C_4H_4O_4$ and a molecular weight of 635.52 It has the following structural formula:



TDF is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25°C 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF [see Microbiology (12.4)].

12 2 Pharmacodynam

<u>Larolac Electrophysiology</u> Efavirenz: The effect of EFV on the QTc interval was evaluated in an open-label, positive and placebo-cor fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B

12.3 Pharmacokinetics Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet: One Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is bioequivalent to one Sustiva tablet (600 mg) plus one EMTRIVA® capsule (200 mg) plus one VIREAD® tablet (300 mg) following single-dose administration to fasting healthy subjects (N=45

Efavirenz: In HIV-1 infected subjects time-to-peak plasma concentrations were approximately 3-5 hours and steady-state plasma concentrations were reached in 6-10 days. In 35 HIV-1 infected subjects receiving EFV 600 mg once daily, steady-state C_{max} was $12.9 \pm 3.7 \mu$ M (mean \pm SD), C_{min} was $5.6 \pm 3.2 \mu$ M, and AUC was $184 \pm 73 \mu$ M-hr. EFV is highly bound (approximately 99.5-99.75%) to human plasma proteins, predominantly albumin. Following administration of ¹⁴C-labeled EFV, 14-34% of the dose was recovered in the urine (mostly as metabolites) and 16-61% was recovered in feces (mostly as parent drug). In *vitro* studies suggest CVP3A and CYP2B6 are the major isozymes responsible for EFV metabolism. EFV has been shown to induce CYP enzymes. resulting in induction of its own metabolism. EFV has a terminal half-life of 52-76 hours after single doses and 40-55 hours after multiple doses

Emtricitabine: Following oral administration, FTC is rapidly absorbed, with peak plasma concentrations occurring at 1-2 hours postdose. Following multiple dose oral administration of FTC to 20 HIV-1 infected subjects, the steady-state plasma FTC C_{max} was 1.8 ± 0.7 µg/mL (mean ± SD) and the AUC over a 24-hour dosing interval was 1.0 \pm 3.1 µg+h/mL. The mean steady-state plasma trough concentration at 24 hours postdose was 0.09 µg/mL. The mean absolute bioavailability of FTC was 93%. Less than 4% of FTC binds to human plasma proteins in vitro, and the binding is independent of concentration over the range of 0.02-200 up(mL, Following administration of radiolabelled FTC, approximately 86% is recovered in the urine and 13% is recovered as metabolites. The metabolites of FTC include 3'-sulfoxide diastereomers and their glucuronic acid conjugate ETC is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with normal renal function of 213 ± 89 mL/min (mean \pm SD). Following a single oral dose,

the plasma FTC half-life is approximately 10 hours. Tenofovir DF: Following oral administration of a single 300 mg dose of TDF to HIV-1 infected subjects in the UC values were 296 \pm 90 ng/mL and 2287 \pm 685 ng•hr/mL, respectively. The oral bioavailability of tenorov from TDF in fasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human plasma proteins

elimination half-life of tenofovir is approximately 17 hours. Effects of Food on Oral Absorption Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet has not been evaluated in the presence of foo

Administration of EFV tablets with a high-fat meal increased the mean AUC and C_{max} of EFV by 28% and 79%, respectively, compared to administration in the fasted state. Compared to fasted administration, dosing of TDF and FTC in combination with either a high-fat meal or a light meal increased the mean AUC and C_{max} of tenofovin by 35% and 15%, respectively, without affecting FTC exposures [see Dosage and Administration (2.2) and Patient Counseling Information (17)].

enofovir DF: There were insufficient numbers from racial and ethnic groups other than Caucasian to adequat

Efavirenz, Emtricitabine, and Tenofovir DF: EFV, FTC, and tenofovir pharmacokinetics are similar in male and

female subjects

Pediatric Patient favirenz: In an open-label trial in NRTI-experienced pediatric subjects (mean age 8 years, range 3-16 years), the pharmacokinetics of FEV in pediatric subjects were similar to the pharmacokinetics in adults who received a 600 mg daily dose of EFV. Based on mean steady-state predicted population pharmacokinetic modeling in pediatric subjects weighing >40 kg receiving the 600 mg dose of EFV, C_{max} was 6.57 µg/mL, C_{min} was 2.82 µg/ mL, and AUC(0.24) was 254.78 µM•hr

Emtricitabine: The pharmacokinetics of FTC at steady state were determined in 27 HIV-1-infected pediatric subjects 13 to 17 years of age receiving a daily dose of 6 mg/kg up to a maximum dose of 240 mg oral solutio Clinical trials of EFV, FTC, or TDF did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for elderly patients should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concompliant disease or the drug thereave Tenofovir DF: Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected pediatric subjects

(12 to less than 18 years). Mean \pm SD C_{aux} and AUC_{bu} are 0.38 \pm 0.13 µg/mL and 3.39 \pm 1.22 µg/m/mL, respectively. Tenofovir exposure achieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar to exposures achieved in adults receiving once-daily doses of TDF 300 mg. Geriatric Patients Pharmacokinetics of EFV, FTC, and tenofovir have not been fully evaluated in the elderly (65 years of age and

older) [see Use in Specific Populations (8.5)].

Patients with Impaired Renal Function Elavirenz: The pharmacokinetics of EFV have not been studied in subjects with renal insufficiency; however

Emtricitabine and Tenofovir DF: The pharmacokinetics of FTC and TDF are altered in subjects with renal impairment. In subjects with creatinine clearance below 50 mL/min, C_{max} and AUC_{nm} of FTC and tenofovir were increased [see Warnings and Precautions (5.7)].

Patients with Hepatic Impairment Efavirenz: A multiple-dose trial showed no significant effect on EFV pharmacokinetics in subjects with mild hepatic impairment (Child-Pugh Class A) compared with controls. There were insufficient data to determine ther moderate or severe hepatic impairment (Child-Pugh Class B or C) affects EFV pharmacokinetics [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].

Emtricitabine: The pharmacokinetics of FTC have not been studied in subjects with hepatic impairment; however, Emtricitabine: Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis FTC is not significantly metabolized by liver enzymes, so the impact of liver impairment should be limited Tenofovir DF: The pharmacokinetics of tenofovir following a 300 mg dose of TDF have been studied in non-HIV infected subjects with moderate to severe hepatic impairment. There were no substantial alterations in tenofovir

pharmacokinetics in subjects with hepatic impairment compared with unimpaired subjects Assessment of Drug Interactions The drug interaction trials described were conducted with either efavirenz, emtricitable, or tenofovir DF or

he components of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet (EFV, FTC, or TDF) as individual agents.

a12h days 2-7

300 mg qd x

7 davs

in lowered plasma concentrations.

Drug

itonavir

Efavirenz: The steady-state pharmacokinetics of EFV and tenofovir were unaffected when EFV and TDF were administered together versus each agent dosed alone. Specific drug interaction trials have not been performe with EFV and NRTIs other than tenofovir, lamivudine, and zidovudine. Clinically significant interactions would

favirenz: The pharmacokinetics of EFV in HIV-1 infected subjects appear to be similar among the racial groups

determine potential pharmacokinetic differences among these populations following the administration of TDF.

Efavirenz has been shown in vivo to cause hepatic enzyme induction, thus increasing the biotra some drugs metabolized by CYP3A and CYP2B6. In vitro studies have shown that EEV inhibited CYP isozymes 209 and 2019 with K values (8.5-17 μM) in the range of observed EV plasma concentrations. In *in vitro* studies EVV did not inhibit CVP2E1 and inhibited CVP2D6 and CVP1A2 (K, values 82-160 μM) only at concentration well above those achieved clinically. Coadministration of EFV with drugs primarily metabolized by CYP2C9

CYP2C19, CYP3A or CYP2B6 isozymes may result in altered plasma concentrations of the coadministered drug. Drugs which induce CYP3A and CYP2B6 activity would be expected to increase the clearance of EFV resulting Drug interaction trials were performed with EFV and other drugs likely to be coadministered or drugs commonly used as probes for pharmacokinetic interaction. There was no clinically significant interaction observed be line, lamivudine, azithromycin, fluconazole, lorazepam, cetirizine, or paroxetine. Single doses

of famotidine or an aluminum and magnesium antacid with simethicone had no effects on EFV exposures. The effects of coadministration of EFV on C_{max} , AUC, and C_{min} are summarized in Table 4 (effect of other drugs on EFV) and Table 5 (effect of EFV on other drugs) see [Drug Interactions (7)]. Table 4: Drug Interactions: Changes in Pharmacokinetic Parameters for EFV in the Presence of the

Coadministered Drug

	Coadminist	erea	Drug			Sir
				ange of EFV Phar		
				arameters ^a (90% (То
Dose of Coadministered Drug (mg)	EFV Dose (mg)	N	C _{max}	AUC	C _{min}	(in me
400/100 mg q12h x 9 days	600 mg qd x 9 days	11, 12⁵	\leftrightarrow	↓ 16 (↓ 38 to ↑15)	↓ 16 (↓ 42 to ↑ 20)	Ca
750 mg q8h x 7 days	600 mg qd x 7 days	10	↓ 12 (↓ 32 to ↑ 13)°	↓ 12 (↓ 35 to ↑ 18)°	↓ 21 (↓ 53 to ↑ 33)	
500 mg q 12h x 8 days	600 mg qd x 10 days	9	↑ 14 (↑ 4 to ↑ 26)	↑ 21 (↑ 10 to ↑ 34)	↑ 25 (↑ 7 to ↑ 46)°	Ep
800 mg tid x 6 days	600 mg qd x 16 days	NA	↑ 11 (↑ 2 to ↑ 20)	↑ 20 (↑ 15 to ↑ 26)	NA	Dil
300 mg qd x 14 days	600 mg qd x 14 days	11	\leftrightarrow	\leftrightarrow	↓ 12 (↓ 24 to ↑1)	De
600 mg x 7 days	600 mg qd x 7 days	12	↓ 20 (↓ 11 to ↓ 28)	↓ 26 (↓ 15 to ↓ 36)	↓ 32 (↓ 15 to ↓ 46)	N-
Artemether 20 mg/ lumefantrine 120 mg tablets (6 4-tablet doses over 3 days)	600 mg qd × 26 days	12	\leftrightarrow	↓17	NA	dil Ett No
40 mg qd x 4 days	600 mg qd x 15 days	14	↓ 12 (↓ 28 to ↑ 8)	\leftrightarrow	↓ 12 (↓ 25 to ↑ 3)	
200 mg qd x 3 days, 200 mg bid x 3 days, then 400 mg qd x 15 days	600 mg qd x 35 days	14	↓ 21 (↓ 15 to ↓ 26)	↓ 36 (↓ 32 to ↓ 40)	↓ 47 (↓ 41 to ↓ 53)	Le
240 mg x 14 days	600 mg qd x 28 days	12	↑ 16 (↑ 6 to ↑ 26)	↑ 11 (↑ 5 to ↑ 18)	↑ 13 (↑ 1 to ↑ 26)	Bu
400 mg po q12h x 1 day then 200 mg po q12h x 8 days	400 mg qd x 9 days	NA	↑ 38ª	↑ 44 ^d	NA	Hy
300 mg po q12h days 2-7	300 mg qd x 7 days	NA	\downarrow 14° (\downarrow 7 to \downarrow 21)	↔ °	NA	Se

 $(\uparrow 6 \text{ to } \uparrow 29)$

	NA = not available
	^a Increase = \uparrow ; Decrease = \downarrow ; No Effect = ↔
d,	^{b.} Parallel-group design; N for EFV + lopinavir/ritonavir, N for EFV alone.
36	≏ 95% CI
n	d. 90% CI not available

Relative to steady-state administration of EFV (600 mg once daily for 9 days)

No effect on the pharmacokinetic parameters of EFV was observed with the following coadministered drug

indinavir, saquinavir soft gelatin capsule, simeprevir, ledipasvir/sofosbuvir, sofosbuvir, clarith itraconazole atorvastatin pravastatin or sertraline

		Presence o	-	Mean % (Change of Coadr	
Coadministered	Dose of	EFV Dose (mg)	N	Pa	ug Pharmacokin rametersª (90%	CI)
Drug	Coadministered Drug (mg)	EFV Dose (mg)	N	C _{max}	AUC	C _{min}
tazanavir	400 mg qd with a light meal d 1-20	600 mg qd with a light meal d	27	↓ 59 (↓ 49 to ↓ 67)	$\begin{array}{c} \downarrow 74 \\ (\downarrow 68 \text{ to } \downarrow 78) \end{array}$	↓ 93 (↓ 90 to ↓ 95)
	400 mg qd d 1-6,	7-20 600 mg qd 2 h	13	↑ 14 ^b	↑ 39 ^b	↑ 48 ^b
	then 300 mg qd d 7-20 with ritonavir 100 mg qd and a light meal	after atazanavir and ritonavir d 7-20		(↓ 17 to ↑ 58)	(↑ 2 to ↑ 88)	(↑ 24 to ↑ 76)
	300 mg qd/ritonavir 100 mg qd d 1-10	600 mg qd with a light snack d	14	↑ 17 (↑ 8 to ↑ 27)	\leftrightarrow	↓ 42 (↓ 31 to ↓ 51)
	(pm), then 400 mg qd/ritonavir 100	11-24 (pm)		(1010121)		(* * * * * * * * *
	mg qd d 11-24 (pm) (simultaneous with EFV)					
inavir	1000 mg q8h x 10 days	600 mg qd x 10 days	20			
		rning dose		↔c	↓ 33° (↓ 26 to ↓ 39)	↓ 39° (↓ 24 to ↓ 51)
	After afte	rnoon dose		↔°	$\begin{array}{c} \downarrow 37^{\circ} \\ (\downarrow 26 \text{ to } \downarrow 46) \end{array}$	$\downarrow 52^{\circ}$ ($\downarrow 47 \text{ to } \downarrow 57$)
	After ev	ening dose		↓ 29 ^c (↓ 11 to ↓ 43)	$\downarrow 46^{\circ}$ ($\downarrow 37 \text{ to } \downarrow 54$)	↓ 57° (↓ 50 to ↓ 63)
inavir/ navir	400/100 mg q12h x 9 days	600 mg qd x 9 days	11, 7ª	↔e	↓ 19° (↓ 36 to ↑ 3)	↓ 39 ^e (↓ 3 to ↓ 62)
ïnavir	750 mg q8h x 7 days	600 mg qd x 7 days	10	↑ 21 (↑ 10 to ↑ 33)	↑ 20 (↑ 8 to ↑ 34)	\leftrightarrow
tabolite •1402				↓ 40 (↓ 30 to ↓ 48)	\downarrow 37 (\downarrow 25 to \downarrow 48)	↓ 43 (↓ 21 to ↓ 59)
1402	500 mg q12h x 8 days	600 mg qd x 10 days	11	(+ 50 10 + 40)	(+ 23 10 + 40)	(* 21 10 * 33)
navir	After AM			↑ 24 (↑ 12 to ↑ 38)	↑ 18 (↑ 6 to ↑ 33)	↑ 42 (↑ 9 to ↑ 86) ^r
	After PN	l dose	\square	\leftrightarrow	↔	↑ 24 (↑ 3 to ↑ 50)
uinavir ⁹	1200 mg q8h x 10 days	600 mg qd x 10 days	12	↓ 50 (↓ 28 to ↓ 66)	↓ 62 (↓ 45 to ↓ 74)	↓ 56
viroc	100 mg bid	600 mg qd	12	$\begin{array}{c} \downarrow 51\\ (\downarrow 37 \text{ to } \downarrow 62) \end{array}$	↓ 45 (↓ 38 to ↓ 51)	↓ 45 (↓ 28 to ↓ 57)
gravir	400 mg single dose	600 mg qd	9	↓ 36 (↓ 2 to ↓ 59)	$\begin{array}{c} \downarrow 36\\ (\downarrow 20 \text{ to } \downarrow 48)\end{array}$	↓ 21 (↓ 51 to ↑ 28)
previr	800 mg tid x 6 days	600 mg qd x 16 days	NA	↓ 8 (↓ 22 to ↑ 8)	↓ 19 (↓ 11 to ↓ 25)	↓ 44 (↓ 26 to ↓ 58)
orevir	150 mg qd × 14 days	600 mg qd × 14 days	23	$\begin{array}{c} \downarrow 51 \\ (\downarrow 46 \text{ to } \downarrow 56) \end{array}$	$\begin{array}{c} \downarrow 71 \\ (\downarrow 67 \text{ to } \downarrow 74) \end{array}$	↓ 91 (↓ 88 to ↓ 92)
asvir/ sbuvir ^ĸ	90/400 mg qd x 14 days	600 mg qd x 14 days	15			
pasvir				↓ 34 (↓ 25 to↓ 41)	↓ 34 (↓ 25 to ↓41)	↓ 34 (↓ 24 to ↓43)
sbuvir				(↓ 20 10↓ 41)	$(\downarrow 20 to \downarrow \uparrow \uparrow)$	NA
31007 ¹ sbuvir ^m	400 mg qd single	600 mg qd x14	16	↔ ↓ 19	\leftrightarrow \leftrightarrow	↔ NA
31007 ¹	dose	days		(↓ 40 to↑ 10) ↓ 23	↓ 16	NA
buvir/	400/100 mg qd ×	600 mg qd × 14		(↓ 16 to↓ 30)	(↓ 24 to↓ 8)	
tasvir ⁿ	14 days	days				
sbuvir			14	↑ 38 (↑ 14 to ↑ 67)	\leftrightarrow	NA
31007 ¹				\downarrow 14 (\downarrow 20 to \downarrow 7)	\leftrightarrow	\leftrightarrow
atasvir				↓ 47	↓ 53	↓ 57
hromycin	500 mg q12h x	400 mg qd x	11	$(\downarrow 57 \text{ to } \downarrow 36)$ $\downarrow 26$	$(\downarrow 61 \text{ to } \downarrow 43)$ $\downarrow 39$	↓ 53
I metabolite	7 days	7 days		(↓ 15 to ↓ 35) ↑ 49	(↓ 30 to ↓ 46) ↑ 34	(↓ 42 to ↓ 63) ↑ 26
azole	200 mg q 12 h	600 mg qd x 14	18	(↑ 32 to ↑ 69) ↓ 37	(↑ 18 to ↑ 53) ↓ 39	(↑ 9 to ↑ 45) ↓ 44
	x 28 days	days		(↓ 20 to ↓ 51)	$(\downarrow 21 \text{ to } \downarrow 53)$	(↓ 27 to ↓ 58)
xy- 1azole	400 (400	4.	$\begin{array}{c} \downarrow 35\\ (\downarrow 12 \text{ to } \downarrow 52) \end{array}$	$\begin{array}{c} \downarrow 37 \\ (\downarrow 14 \text{ to } \downarrow 55) \\ \downarrow 50 \end{array}$	· · · · · · · · · · · · · · · · · · ·
onazole	400 mg (oral suspension) bid × 10 and 20 days	400 mg qd × 10 and 20 days	11	\downarrow 45 (\downarrow 34 to \downarrow 53)	$\downarrow 50 \\ (\downarrow 40 \text{ to } \downarrow 57)$	NA
utin	300 mg qd x 14 days	600 mg qd x 14 days	9	↓ 32 (↓ 15 to ↓ 46)	\downarrow 38 (\downarrow 28 to \downarrow 47)	↓ 45 (↓ 31 to ↓ 56)
nether/ fantrine	Artemether 20 mg/lumefantrine	600 mg qd x 26 days	12	((. == (0 + 1/)	
	120 mg tablets (6 4-tablet doses over	,, U				
nether Iroartemisinin	3 days)			$\downarrow 21$ $\downarrow 38$	$\downarrow 51$ $\downarrow 46$	NA NA
fantrine /astatin	10 mg gd x 4 davs	600 mg qd x 15	14	$\downarrow 38$ \leftrightarrow $\downarrow 14$	$\downarrow 46$ $\downarrow 21$ $\downarrow 43$	NA NA ↓69
	y qu x 4 ddyS	days	'	(↓ 1 to ↓ 26)	(↓ 34 to ↓ 50)	(↓ 49 to ↓ 81)
active Jding				\downarrow 15 (\downarrow 2 to \downarrow 26)	\downarrow 32 (\downarrow 21 to \downarrow 41)	\downarrow 48 (\downarrow 23 to \downarrow 64)
bolites) astatin	40 mg qd x 4 days	600 mg qd x 15	13	↓ 32 (↓ 59 to ↑ 12)	$\downarrow 44$ ($\downarrow 26 \text{ to } \downarrow 57$)	↓ 19 (↓ 0 to ↓ 35)
astatin	40 mg qd x 4 days	days 600 mg qd x 15 days	14	$(\downarrow 59 \text{ to } 12)$ $\downarrow 72$ $(\downarrow 63 \text{ to } \downarrow 79)$	$\begin{array}{c} (\downarrow 26 \text{ to } \downarrow 57) \\ \downarrow 68 \\ (\downarrow 62 \text{ to } \downarrow 73) \end{array}$	$(\downarrow 0 \text{ to } \downarrow 35)$ $\downarrow 45$ $(\downarrow 20 \text{ to } \downarrow 62)$
active		Juyo		↓ 68	↓ 60	(↓ 20 t0 ↓ 62 NA ^h
ding polites)				(↓ 55 to ↓ 78)	(↓ 52 to ↓ 68)	
mazepine	200 mg qd x 3 days, 200 mg bid x 3 days then 400	600 ma ed v 44	10	$\begin{array}{c} \downarrow 20 \\ (\downarrow 15 \text{ to } \downarrow 24) \end{array}$	$ \begin{array}{c} \downarrow 27 \\ (\downarrow 20 \text{ to } \downarrow 33) \end{array} $	↓ 35 (↓ 24 to ↓ 44)
	x 3 days, then 400 mg qd x 29 days	600 mg qd x 14 days	12			
de metabolite				\leftrightarrow	\leftrightarrow	↓ 13 (↓ 30 to ↑ 7)
em.	240 mg x 21 days	600 mg qd x 14 days	13	↓ 60 (↓ 50 to ↓ 68)	↓ 69 (↓ 55 to ↓ 79)	↓ 63 (↓ 44 to ↓ 75)
etyl diltiazem				↓ 64 (↓ 57 to ↓ 69)	\downarrow 75 (\downarrow 59 to \downarrow 84)	↓ 62 (↓ 44 to ↓ 75)
nodesmethyl				↓ 28	↓ 37	↓ 37
zem yl estradiol/	0.035 mg/0.25 mg	600 mg qd x 14	-	(↓ 7 to ↓ 44)	(↓ 17 to ↓ 52)	
estimate	x 14 days	days				
yl estradiol Igestromin			21 21	\leftrightarrow \downarrow 46	\leftrightarrow $\downarrow 64$	↔ ↓ 82
			6	(↓ 39 to ↓ 52) ↓ 80	$(\downarrow 62 \text{ to } \downarrow 67)$ $\downarrow 83$	(↓ 79 to ↓ 85) ↓ 86
norgestrel hadone	Stable maintenance	600 mg qd x	11	(↓ 77 to ↓ 83) ↓ 45	(↓ 79 to ↓ 87) ↓ 52	(↓ 80 to ↓ 90) NA
ropion	35-100 mg daily 150 mg single dose	14-21 days 600 mg qd x 14	13	$(\downarrow 25 \text{ to } \downarrow 59)$ $\downarrow 34 (\downarrow 21 \text{ to}$	$(\downarrow 33 \text{ to } \downarrow 66)$ $\downarrow 55 (\downarrow 48 \text{ to}$	NA
	(sustained-release)	days		↓ 47)	↓ 62)	
oxybupropion	50 co co to co to co	000		↑ 50 (↑ 20 to ↑ 80)	↔	NA
ine	50 mg qd x 14 days	600 mg qd x 14 days	13	$\begin{array}{c} \downarrow 29\\ (\downarrow 15 \text{ to } \downarrow 40)\end{array}$	$\begin{array}{c} \downarrow 39\\ (\downarrow 27 \text{ to } \downarrow 50) \end{array}$	↓ 46 (↓ 31 to ↓ 58)

			Mean % Change of Coadministered Drug Pharmacokinetic Parameters ^a (90% Cl)			
nistered 'ug	Dose of Coadministered Drug (mg)	EFV Dose (mg)	N	C _{max}	AUC	C _{min}
	400 mg po q12h x 1 day then 200 mg po q12h x 8 days	400 mg qd x 9 days	NA	↓ 61 ⁱ	↓ 77 ⁱ	NA
	300 mg po q 12 h days 2-7	300 mg qd x 7 days	NA	↓ 36 ⁱ (↓ 21 to ↓ 49)		NA
ole	400 mg po q12h days 2-7	300 mg qd x 7 days	NA	↑ 23 ^j (↓ 1 to ↑ 53)	↓ 7 ^j (↓ 23 to ↑13)	NA

NA= not available LIncrease = ↑· Decrease = ↓· No Effect = ↔

Compared with atazanavir 400 mg qd alone Comparator dose of indinavir was 800 mg g8h × 10 days

Parallel-group design; N for EFV + loginavir/ritonavir, N for loginavir/ritonavir alone.
 Values are for lopinavir. The pharmacokinetics of ritonavir 100 mg q12h are unaffected by concurrent EFV.

Soft Gelatin Capsule available because of insufficient data.

90% CI not available.

Dri

Relative to steady-state administration of voriconazole (400 mg for 1 day, then 200 mg po g12h for 2 days udy conducted with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet coadm HARVONI.

The predominant circulating nucleoside metabolite of sofosbuvi conducted with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet coadministered with SOVALDI® (sofosbuvir).

Study conducted with efavirenz, emtricitabine and tenofovir disoproxil fumarate tablet coadministered with Emtricitabine and Tenofovir DF: The steady-state pharmacokinetics of FTC and tenofovir were unaffected when (18%), and M230I/L (11%).

FTC and TDF were administered together versus each agent dosed alone. In vitro and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP

nediated interactions involving FTC and tenofovir with other medicinal products is low. TDF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. When TDF is coadministered with an inhibitor of these transporters, an increase in absorption may be observed. No clinically significant drug interactions have been observed between FTC and famciclovir, indinavir sofosbuvir/velpatasvir, stavudine, TDF, and zidovudine. Similarly, no clinically significant drug interactions ve been observed between TDF and abacavir, EFV, FTC, entecavir, indinavir, lamivudine, lopin nethadone, nelfinavir, oral contraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials

conducted in healthy volunteers. Following multiple dosing to HIV-negative subjects receiving either chronic methadone maintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state tenofovir pharmacokinetics were similar to those Efavirenz, Emtricitabine, and Tenofovir DF: Cross resistance has been recognized among NNRTIs. Cross observed in previous trials, indicating a lack of clinically significant drug interactions between these agents

The effects of coadministered drugs on the C_{max} , AUC, and C_{min} of tenofovir are shown in Table 6. The effects of oadministration of TDF on Cmax, AUC, and Cmin of coadministered drugs are shown in Table 7.
 Table 6: Drug Interactions: Changes in Pharmacokinetic Parameters for Tenofovir in the Presence of the

Coadministered Drug	Dose of Coadministered Drug (mg)	N	Mean% Change of Tenofovir Pharmacokinetic Parameters ^e (90% CI)				
			C _{max}	AUC	C _{min}		
Atazanavir ^d	400 once daily x 14 days	33	↑ 14 (↑ 8 to ↑ 20)	↑ 24 (↑ 21 to ↑ 28)	↑ 22 (↑ 15 to ↑ 30)		
Atazanavir/ ritonavir ^d	300/100 once daily	12	↑ 34 (↑ 20 to ↑ 51)	↑ 37 (↑ 30 to ↑ 45)	↑ 29 (↑ 21 to ↑ 36)		
Darunavir/ ritonavir ^e	300/100 twice daily	12	↑ 24 (↑ 8 to ↑ 42)	↑ 22 (↑ 10 to ↑ 35)	↑ 37 (↑ 19 to ↑ 57)		
Didanosine ^r	250 or 400 once daily x 7 days	14	\leftrightarrow	\leftrightarrow	\leftrightarrow		
Ledipasvir/sofosbuvir	90/400 once daily	15	↑ 79 (↑ 56 to ↑ 104)	↑ 98 (↑ 77 to ↑ 123)	↑ 163 (↑ 132 to ↑ 197		
Lopinavir/ ritonavir	400/100 twice daily x 14 days	24	\leftrightarrow	↑ 32 (↑ 25 to ↑ 38)	↑ 51 (↑ 37 to ↑ 66)		
Sofosbuvir	400 once daily	16	↑ 25 (↑ 8 to ↑ 45)	\leftrightarrow	\leftrightarrow		
Sofosbuvir/ velpatasvir	400/100 once daily	15	↑ 77 (↑ 53 to ↑ 104)	↑ 81 (↑ 68 to ↑ 94)	↑ 121 (↑ 100 to ↑ 143		
Tingana vig/ site and vig	500/100 twice daily	22	↓ 23 (↓ 32 to ↓ 13)	↓ 2 (↓ 9 to ↑ 5)	↑ 7 (↓ 2 to ↑ 17)		
Tipranavir/ ritonavir®	750/200 twice daily (23 doses)	20	\downarrow 38 (\downarrow 46 to \downarrow 29)	↑ 2 (↓ 6 to ↑ 10)	↑ 14 (↑ 1 to ↑ 27)		

^a Subjects received TDF 300 mg once daily Increase = \uparrow ; Decrease = \downarrow ; No Effect = \leftarrow

eyataz Prescribing Information. Prezista Prescribing Information Aptivus Prescribing Information

Subjects received didanosine buffered tablets.

Table 7: Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of TDF^a

Coadministered Dose of Coadministered N Mean % Change of Co-administered Drug

Drug	Drug (mg)		(90% CI)		
			C _{max}	AUC	C _{min}
A	400 once daily x 14 days	34	↓ 21 (↓ 27 to ↓ 14)	↓ 25 (↓ 30 to ↓ 19)	↓ 40 (↓ 48 to ↓ 32)
Atazanavir ^d	Atazanavir/ritonavir 300/100 once daily x 42 days	10	↓ 28 (↓ 50 to ↑ 5)	$\downarrow 25^{\circ}$ ($\downarrow 42 \text{ to } \downarrow 3$)	↓ 23° (↓ 46 to ↑ 10)
Darunavir ^r	Darunavir/ritonavir 300/100 once daily	12	↑ 16 (↓ 6 to ↑ 42)	↑ 21 (↓ 5 to ↑ 54)	↑ 24 (↓ 10 to ↑ 69)
Didanosine ⁹	250 once, simultaneously with TDF and a light meal ^h	33	\downarrow 20 ⁱ (\downarrow 32 to \downarrow 7)	↔ ⁱ	NA
Lopinavir	Lopinavir/ritonavir 400/100 twice daily x 14 days	24	\leftrightarrow	\leftrightarrow	\leftrightarrow
Ritonavir	Lopinavir/ritonavir 400/100 twice daily x 14 days	24	\leftrightarrow	\leftrightarrow	\leftrightarrow
Tipropoviri	Tipranavir/ritonavir 500/100 twice daily	22	\downarrow 17 (\downarrow 26 to \downarrow 6)	↓ 18 (↓ 25 to ↓ 9)	↓ 21 (↓ 30 to ↓ 10)
Tipranavir ⁱ	Tipranavir/ritonavir 750/200 twice daily (23 doses)	20	↓ 11 (↓ 16 to ↓ 4)	↓ 9 (↓ 15 to ↓ 3)	↓ 12 (↓ 22 to 0)

Subjects received TDF 300 mg once daily

Revataz Prescribing Information.

 C_{min} values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.

Prezista Prescribing Informatio Videx EC Prescribing Information. Subjects received didanosine enteric-coated capsules.

¹ 373 kcal, 8.2 g fat. Compared with didanosine (enteric-coated) 400 mg administered alone under fasting conditions.

Aptivus Prescribing Information 12.4 Microbiology

predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA phosphaturia, to the bone toxicity is not known polymerases α , β , γ , and δ are not inhibited by EFV.

Emtricitabine: Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form FTC 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 RT by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which esults in chain termination. Emtricitabine 5'-triphosphate is a weak inhibitor of mammalian DNA polymerases α , β , ε , and mitochondrial DNA polymerase γ .

requires initial dester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation into DNA, by DNA chain rmination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial Study 934: Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled DNA polymerase γ .

of FTC and EFV together, EFV and tenofovir together, and FTC and tenofovir together, additive to synergistic antiviral effects were observed.

Efavirenz: The concentration of EFV inhibiting replication of wild-type laboratory adapted strains and clinical solates in cell culture by 90-95% (EC_{90.95}) ranged from 1.7-25 nM in lymphoblastoid cell lines, peripheral lood mononuclear cells, and macrophage/monocyte cultures. Efavirenz demonstrated additive antiviral activity against HIV-1 in cell culture when combined with non-nucleoside reverse transcriptase inhibitors (NNRTIS virdine and nevirapine), nucleoside reverse transcriptase inhibitors (NRTIs) (abacavir, didanosine amivudine, stavudine, zalcitabine, and zidovudine), protease inhibitors (PIs) (amprenavir, indinavir, lopinavir nelfinavir, ritonavir, and saquinavir), and the fusion inhibitor enfuvirtide. Efavirenz demonstrated additive to antagonistic antiviral activity in cell culture with atazanavir. Efavirenz demonstrated antiviral activity against clade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N), but had reduced antiviral activity against group O viruses. Efavirenz is not active against HIV-2

Emtricitabine: The antiviral activity in cell culture of FTC against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell line, and peripheral blood mononuclear cells. The 50% effective concentration (EC_{so}) values for FTC were in the range of 0.0013-0.64 μ M (0.0003-0.158 μ g/mL) In drug combination studies of FTC with NRTIs (abacavir, lamivudine, stavudine, zalcitabine, and zidovudine) NNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, nelfinavir, ritonavir, and saquinavir), additive t vneroistic effects were observed. Emtricitable displayed antiviral activity in cell culture against HIV-1 clades B, C, D, E, F, and G (EC₅₀ values ranged from 0.007-0.075 μ M) and showed strain-specific activity against HIV-2 C., values ranged from 0.007-1.5 µM)

Tenofovir DF: The antiviral activity in cell culture of tenofovir against laboratory and clinical isolates of HIV-1 was a Subjects who were responders at Week 48 or Week 96 (HIV-1 RNA <400 conjes/mL) but did not consent to continue trial after Week 48 or Week 96 were excluded from analysis. ^b Subjects achieved and maintained confirmed HIV-1 RNA <400 copies/mL through Weeks 48 and 14 istoid cell lines, primary m age cells and peripheral blood lymphocytes μ e EC_{so} values for tenofovir were in the range of 0.04-8.5 μ M. In drug combination studies of tenofovir with NRTIS (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine). NNRTIS (delavirdine, EFV, and Includes confirmed viral rebound and failure to achieve confirmed HIV-1 RNA <400 copies/mL through Week</p> nerrispice (adaptive), induitosine, fainvourie, savourie, zacitationie, and zuovourie), invitrie (oceavitatile, t. v. and nevirapine), and Pis (amperanvir, indinavir, nefinavir, ritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and ^{d.} Includes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other reasons. O (EC₅₀ values ranged from 0.5-2.2 µM) and showed strain-specific activity against HIV-2 (EC₅₀ values ranged Through Week 48, 84% and 73% of subjects in the FTC + TDF group and the zidovudine/lamivudine group rom 1.6 µM-5.5 µM)

respectively, achieved and maintained HIV-1 RNA <400 copies/mL (71% and 58% through Week 144). The difference in the proportion of subjects who achieved and maintained HIV-1 RNA <400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reason EFV, FTC, and TDF: HIV-1 isolates with reduced susceptibility to the combination of FTC and tenofovir have been Selected in cell culture and in clinical trials. Genotypic analysis of these isolates identified the M184V/I and/or K65R amino acid substitutions in the viral RT. In addition, a K70E substitution in HIV-1 reverse transcriptase in the zidovudine/lamivudine group in this open-label trial. In addition, 80% and 70% of subjects in the FTC + TDF group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA <50 copies/ mL through Week 48 (64% and 56% through Week 144). The mean increase from baseline in CD4* cell count has been selected by tenofovir and results in reduced susceptibility to tenofovir. was 190 cells/mm³ in the FTC + TDF group and 158 cells/mm³ in the zidovudine/lamivudine group at Week 48 In a clinical trial of treatment-naïve subjects [Study 934, see Clinical Studies (14)] resistance analysis was

(312 and 271 cells/mm³ at Week 144). rmed on HIV-1 isolates from all confirmed virologic failure subjects with greater than 400 copies/mL Through 48 weeks, 7 subjects in the FTC + TDF group and 5 subjects in the zidovudine/lamivudine group of HIV-1 RNA at Week 144 or early discontinuations. Genotypic resistance to EFV, predominantly the K103N substitution, was the most common form of resistance that developed. Resistance to EFV occurred in 13/19 experienced a new CDC Class C event (10 and 6 subjects through 144 weeks). nalyzed subjects in the FTC + TDF group and in 21/29 analyzed subjects in the zidovudine/lami Study 073; Study 073 was a 48-week open-label, randomized clinical trial in subjects with stable virologic dose combination group. The M184V amino acid substitution, associated with resistance to FTC and lamivudine, suppression on combination antiretroviral therapy consisting of at least two NRTIs administered in combination with a protease inhibitor (with or without ritonavir) or a NNRTI. was observed in 2/19 analyzed subject isolates in the FTC + TDF group and in 10/29 analyzed subject isolates in nivudine group. Through 144 weeks of Study 934, no subjects developed a detectable K65R To be enrolled, subjects were to have HIV-1 RNA <200 copies/mL for at least 12 weeks on their current regime substitution in their HIV-1 as analyzed through standard genotypic analysis. nrior to trial entry with no known HIV-1 substitutions conferring resistance to the components of Efavirenz ricitabine and Tenofovir disoproxil fumarate tablet and no history of virologic failure.

In a clinical trial of treatment-naïve subjects, isolates from 8/47 (17%) analyzed subjects receiving TDF developed the K65R substitution through 144 weeks of therapy; 7 of these occurred in the first 48 weeks of treatment and one at Week 96. In treatment experienced subjects, 14/304 (5%) of TDF treated subjects with virologic failure through Week 96 showed greater than 1.4-fold (median 2.7) reduced susceptibility to tenofovir. Genotypic analysis of the resistant isolates showed a substitution in the HIV-1 RT gene resulting in the K65R amino acid substitution

favirenz: Clinical isolates with reduced susceptibility in cell culture to EFV have been obtained. The most frequently observed amino acid substitution in clinical trials with EFV is K103N (54%). One or more BT in substitutions at amino acid positions 98, 100, 101, 103, 106, 108, 188, 190, 225, 227, and 230 were observed in subjects failing treatment with EFV in combination with other antiretrovirals. Other resistance substitutions At Week 48, 89% and 87% of subjects who switched to Efavirenz, Emtricitabine and Tenofovir disoprox fumarate tablet maintained HIV RNA <200 copies/mL and <50 copies/mL, respectively, compared to 88% and bserved to emerge commonly included L100I (7%), K101E/Q/R (14%), V108I (11%), G190S/T/A (7%), P225H 85% who remained on SBR; this difference was not statistically significant. No changes in CD4⁺ cell counts from baseline to Week 48 were observed in either treatment arm.

HIV-1 isolates with reduced susceptibility to EFV (greater than 380-fold increase in EC₉₀ value) emerged rapidly 16 HOW SUPPLIED/STORAGE AND HANDLING under selection in cell culture. Genotypic characterization of these viruses identified subs utions resulting in avirenz, Entricitabine and Tenofovir disoproxil fumarate tablets are pink colored, capsule-shaped, biconvex, m-coated, debossed with 'C210'on one side and plain on other side. single amino acid substitutions L100I or V179D, double substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in RT Each bottle contair

Emtricitabine: Emtricitabine-resistant isolates of HIV-1 have been selected in cell culture and in clinical trials 30 tablets (NDC 76282-678-30) and silica gel desiccant, and is closed with a child-resistant closure Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. Genotypic analysis of these isolates showed that the reduced susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon 184 which resulted in an amino acid substitution of methionine by Keep container tightly closed. valine or isoleucine (M184V/I).

 valine or isoleucine (M184V/l).
 Dispense only in original container.
 Do not use if seal over bottle opening is broken or missing. viruses expressed a K65R substitution in RT and showed a 2- to 4-fold reduction in susceptibility to tenofovir.

resistance has also been recognized among certain NRTIs. The M184V/I and/or K65R substitutions selected in cell culture by the combination of FTC and tenofovir are also observed in some HIV-1 isolates from subjects ling treatment with tendowir in combination with either lamivuline or FTC, and either abacavir or didanosine. erefore, cross resistance among these drugs may occur in patients whose virus harbors either or both of these amino acid substitutions.

Efavirenz: Clinical isolates previously characterized as EFV resistant were also phenotypically resistant in cell L'avrienze official solvates previously virial actenze da cir y restanti viere also prieriographi desistant ni cen culture to delavirdine and nevirapine compared to baseline. Delavirdine - and/or nevirapine-resistant clinical viral isolates with NNRTI resistance-associated substitutions (A986, L100I, K101E/P, K103N/S, V106A, Y181X, Y188X, G190X, P225H, F227L, or M230L) showed reduced susceptibility to EFV in cell culture. Greater than 90% of NRTI-resistant isolates tested in cell culture retained susceptibility to EFV.

Inform patients that a common side effect is rash, and that rashes usually go away without any change in Emtricitabine: Emtricitabine-resistant isolates (M184V/I) were cross resistant to lamivudine but retained treatment. However, since rash may be serious, advise patients to contact their physician promptly if rash susceptibility in cell culture to didanosine, stavudine, tenofovir, zidovudine, and NNRTIs (delavirdine, EFV, and occurs [see Warnings and Precautions (5.2)]. evirapine). HIV-1 isolates containing the K65B substitution, selected in vivo by abacavir, didanosine, and Hepatotoxicity ofovir, demonstrated reduced susceptibility to inhibition by FTC. Viruses harboring Inform patients to watch for early warning signs of liver inflammation or failure, such as fatigue, weakness reduced susceptibility to stavudine and zidovudine (M41L, D67N, K70R, L210W, T215Y/F, and K2190/E) or didanosine (L74V) remained sensitive to FTC. Tenofovir DF: Cross resistance has been observed among NRTIs. The K65R substitution in HIV-1 RT selected Warnings and Precautions (5.3) and Adverse Reactions (6.1)].

by tenofovir is also selected in some HIV-1 infected patients treated with abacavir, or didanosine. HIV-1 Drug Interactions Advise patients that Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet may interact with many solates with the K65R substitution also showed reduced susceptibility to FTC and lamivudine. Therefore, cross resistance among these drugs may occur in patients whose virus harbors the K65R substitution. The K70E substitution selected clinically by TDF results in reduced susceptibility to abacavir, didanosine, FTC, and drugs; therefore, advise patients to report to their healthcare provider the use of any other medication, including other drugs for treatment of hepatitis C virus [see Warnings and Precautions (5.4) and Drug Interactions (7) amivudine, HIV-1 isolates from subjects (N=20) whose HIV-1 expressed a mean of 3 zidovudine-associate Psychiatric Symptom RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K2190/E/N) showed a 3.1-fold decrease Inform patients that serious psychiatric symptoms including severe depression, suicide attempts in the susceptibility to tenofovir. Subjects whose virus expressed an L74V substitution without zidovudine resistance associated substitutions (N=8) had reduced response to TDF. Limited data are available for patients whose virus expressed a Y115F substitution (N=3), Q151M substitution (N=2), or T69 insertion (N=4), all of whom had a reduced respons

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility nz: Long-term carcinogenicity studies in mice and rats were carried out with EFV. Mice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of hepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas were increased above background in females. No increases in tumor cidence above background were seen in males. In studies in which rats were administered EFV at doses of 0. 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence above background were observed. The systemic exposure (based on AUCs) in mice was approximately 1.7-fold that in humans receiving the 600-mg/ day dose. The exposure in rats was lower than that in humans. The mechanism of the carcinogenic potential is own. However, in genetic toxicology assays, EFV showed no evidence of mutagenic or clastogenic activity in a battery of in vitro and in vivo studies. These included bacterial mutation assays in S. typhimurium and E coli, mammalian mutation assays in Chinese hamster ovary cells, chromosome aberration assays in human se hamster ovary cells, and an *in vivo* mouse bone ma assay. Given the lack of genotoxic activity of EFV, the relevance to humans of neoplasms in EFV-treated mice is not known

Efavirenz did not impair mating or fertility of male or female rats, and did not affect sperm of treated male rats. e reproductive performance of offspring born to female rats given EFV was not affected. Because of the rapid clearance of EFV in rats, systemic drug exposures achieved in these studies were equivalent to or below those achieved in humans given therapeutic doses of EFV.

Emtricitabine: In long-term carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure at the therapeutic dose of

Apprise patients of the potential harm to the fetus if Efavirenz, Emtricitabine and Tenofovir disoproxil fumarat 200 mg/day) or in rats at doses up to 600 mg/day (31 times the human systemic exposure at the therapeutic dose). tablet is used during the first trimester of pregnancy, or if the patient becomes pregnant while taking this Emtricitabine was not genotoxic in the reverse mutation bacterial test (Ames test), or the mouse lymphoma or drug. Instruct adults and adolescents of childbearing potential receiving Efavirenz, Emtricitabine and Tenofovi mouse micronucleus assays. Emtricitabine did not affect fertility in male rats at approximately 140-fold or in male and female mice at approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily dose. Fertility was normal in the offspring of mice exposed daily from before birth (in utero) through sexual maturity with other methods of contraception, including oral or other hormonal contraception. Because of the long half-life of EFV, recommend use of adequate contraceptive measures for 12 weeks after discontinuation of Efavirenz, at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended 200 mg Emtricitabine and Tenofovir disoproxil fumarate tablet [see Use in Specific Populations (8.1, 8.3)]. daily dose.

Tenofovir DF: Long-term oral carcinogenicity studies of TDF in mice and rats were carried out at exposures
Bone Loss and Mineralization Defects HIV-1 infection. At the high dose in female mice, liver adenomas were increased at exposures 16 times that in numans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in monitoring may be performed in patients who have a history of pathologic bone fracture or other risk factors for humans at the therapeutic dose. osteoporosis or bone loss [see Warnings and Precautions (5.9)]

TDF was mutagenic in the *in vitro* mouse lymphoma assay and negative in an *in vitro* bacterial mutagenicity test (Ames test). In an *in vivo* mouse micronucleus assay, TDF was negative when administered to male mice. Inform patients that convulsions have been reported with the use of FEV a component of Efavirenz minimipatients that conversions have been reported that the decision of the provide that the second provide the second provide the second provided There were no effects on fertility, mating performance, or early embryonic development when TDF was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area gestation. There was, however, an alteration of the estrous cycle in female rats. Lactic Acidosis and Severe Hepatomegaly Inform patients that lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been

13.2 Animal Toxicology and/or Pharmacology ed convulsions were observed in 6 of 20 monkeys receiving EFV at doses yielding plasma reported. Treatment with Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet should be suspende virenz: Nonsu: nationt who develope clinical symptoms suggestive of lactic a AUC values 4- to 13-fold greater than those in humans given the reco Warnings and Precautions (5.11)] Tenofovir DF: Tenofovir and TDF administered in toxicology studies to rats, dogs, and monkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed in humans caused bone toxicity. In monkeys Immune Reconstitution Syndrome Inform patients that in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms he bone toxicity was diagnosed as osteomalacia. Osteomalacia observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced

hone mineral density. The mechanism(s) underlying hone toxicity is unknown

Evidence of renal toxicity was noted in 4 animal species administered tenofovir and TDF. Increases in serum symptoms of infection [see Warnings and Precautions (5.12)] creatinine, BUN, glycosuria, proteinuria, phosphaturia and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2- to Fat Redistribution Efavirenz: EFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated 20-times higher than those observed in humans. The relationship of the renal abnormalities, particularly the Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy, including Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet and that the cause and longterm health effects of these conditions are not known [see Warnings and Precautions (5.13)]. **14 CLINICAL STUDIES**

 14 CLINICAL STUDIES

 Clinical Study 934 (NCT00112047) supports the use of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet in antiretroviral treatment-naive HIV-1 infected patients.
 Dosing Instructions

 Advise patients to take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet or ally on an empty
 Advise patients to take Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet or ally on an empty

 timarate table in antiretoryiral treatment-naive HV-1 infected patients. Clinical Study 073 (NCT00365612) provides clinical experience in subjects with stable, virologic suppression

Tenofovir DF: TDF is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. TDF In antiretroviral treatment-experienced patients, the use of Efavirenz, Emtricitabine and Tenofovir disoproxil history or by genotypic or phenotypic testing [see Microbiology (12.4)].

Lactation Instruct n multicenter trial comparing FTC + TDF administered in combination with EFV versus zidovudine/lamivudine ct patients not to breastfeed because HIV-1 can be passed to the baby in the breast milk [see Use in *Activital Activity Etavirenz, Entricitabine, and Tenofovir DF:* In combination studies evaluating the antiviral activity in cell culture Specific Populations (8.2)]. **Disclaimer:** Other brands listed are the registered trademarks of their respective owners and are not trademarks EFV. Subjects had a mean age of 38 years (range 18-80); 86% were male, 59% were Caucasian, and 23% were Black. The man baseline D4' cell count was 245 cells/ma³ (range 2-1191), and median baseline plasma HIV-1 RNA was 5.01 log₁₀ copies/mL (range 3.56-6.54). Subjects were stratified by baseline CD4⁺ cell count Manufactured by: (< or ≥200 cells/mm³), and 41% had CD4⁺ cell counts <200 cells/mm³. Fifty-one percent (51%) of subjects had Genvion Corporat (< of 2200 Censimility, and 41 > inde 42 > cen counts <200 Censimility - inde 200 Censimility, and 41 > of subjects had baseline virtal loads > 100,000 copies/mL. Treatment outcomes through 48 and 144 weeks for those subjects who did not have EFV resistance at baseline (N=487) are presented in Table 8. Winnipeg, Manitoba R2J 4K2 Canada Manufactured for:

Table 8 Virologic Outcomes of Randomized Treatment at Weeks 48 and 144 (Study 934)									
Outcomes	At Wee	ek 48	At Week 144						
	FTC + TDF +EFV (N=244)	AZT/3TC +EFV (N=243)	FTC + TDF +EFV (N=227) ^a	AZT/3TC +EFV (N=229) ^a					
Responder ^b	84%	73%	71%	58%					
Virologic failure ^c	2%	4%	3%	6%					
Rebound	1%	3%	2%	5%					
Never suppressed	0%	0%	0%	0%					
Change in antiretroviral regimen	1%	1%	1%	1%					
Death	<1%	1%	1%	1%					
Discontinued due to adverse event	4%	9%	5%	12%					
Discontinued for other reasons ^d	10%	14%	20%	22%					

The trial compared the efficacy of switching to Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate ta or staying on the baseline antiretroviral regimen (SBR). Subjects were randomized in a 2:1 ratio to switch to Eravienz, Emtricitabine and Tenofovir disporval fumarate table (N=203) or stay on SBR (N=97). Subjects had a mean age of 43 years (range 22-73 years); 88% were male, 68% were white, 29% were Black or African-American, and 3% were of other races. At baseline, median CD4⁺ cell count was 516 cells/mm³, and 96% had HIV-1 RNA <50 copies/mL. The median time since onset of antiretroviral heavy was 3 years, and 88% of subjects were receiving their first antiretroviral regimen at trial enrollment.

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information

Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV

Inform patients that severe acute exacerbations of hepatitis B have been reported in patients who an coinfected with HBV and HIV-1 and have discontinued FTC or TDF, and may occur with discontinuation o favirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Advise patients not to discontinue Efavire Emtricitabine and Tenofovir disoproxil fumarate tablet without first informing their healthcare provider. All patients should be tested for HBV infection before or when starting Efavirenz. Emtricitabine and Tenofovi disoproxil fumarate tablet and those who are infected with HBV need close medical follow-up for several more after stopping Efavirenz. Emtricitable and Tenofovir disoproxil fumarate tablet to monitor for exacerbations of hepatitis [see Warnings and Precautions (5.1)]

- aggressive behavior, delusions, paranoia, psycholis-like symptoms, and catatonia have been reported in patients receiving EFV, a component of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet *[see* Warnings and Precautions (5.5)]. lvise patients to seek immediate medical evaluation if they experience severe psychiatric adverse experiences
- Advise patients to inform their physician of any history of mental illness or substance abuse.
- Nervous System Symptoms Inform patients that central nervous system symptoms (NSS) including dizziness, insomnia, impaired concentration, drowsiness, and abnormal dreams, are commonly reported during the first weeks of therapy with EFV, a component of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Dosing at bedtime may improve the tolerability of these symptoms, which are likely to improve with continue
- Alert patients to the potential for additive effects when Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet is used concomitantly with alcohol or psychoactive drugs. Instruct patients that if they experience NSS to avoid potentially hazardous tasks such as driving or
- operating machinery [see Warnings and Precautions (5.6) and Dosage and Administration (2.2)] Inform patients that there is a risk of developing late-onset neurotoxicity, including data and encephalopathy, which may occur months to years after beginning therapy with EFV, a component of Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet [see Warnings and Precautions (5.6)].

New Onset or Worsening Renal Impairment orm patients that renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported. Advise patients to avoid using Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet with rrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) [see Warnings and recautions (5.7)]

Embryo-Fetal Toxicity

are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. Advise patients to inform their healthcar

stomach and that it is important to take Efavirenz. Emtricitable and Tenofovir disoproxil fumarate tablet of and no history of virologic failure who switched from their current regimen to Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet. Pregnancy Registry

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate tablet during pregnancy [see Use in Specific Populations (8.1)].

Exelan Pharmaceuticals, Inc. Boca Raton, FL 33432

Revised: 12/2020